Podcasts about blood institute

Chronic obstructive pulmonary disease, referred to as COPD, is a progressive disease which can, over time, limit your ability to do basic activities such as walking, cooking or taking care of yourself. According to the National Heart, Lung and Blood Institute, it is the sixth leading cause of death in the U.S. and is two times more common in rural areas than it is in large cities. Tushi Singh, M.D., Texas Tech Physicians pulmonologist, is our guest for this episode. Dr. Singh explains to us what causes COPD, what treatments are available and what we can do to protect ourselves from developing COPD. 

On this MADM, Sean Coady with the National Heart, Lung, and Blood Institute is sharing about the importance of heart health & beyond in rural communities. Listen & share. Sponsor: The SIMRP

On tonight's show, I have Sean Coady with National Heart, Lung, and Blood Institute (NHLBI) & Chef Jamie Gwen!

On tonight's show, I'll have Sean Coady, Deputy Branch Chief in the Epidemiology Branch of the Division of Cardiovascular Sciences, at the National Heart, Lung, and Blood Institute to talk about heart health in rural areas and Lance Taylor with CEI Bookstore / Truth Publications to share about their progress after a tornado destroyed their business location in Athens.

On this MADM, I have Sean Coady, Deputy Branch Chief in the Epidemiology Branch of the Division of Cardiovascular Sciences, at the National Heart, Lung, and Blood Institute to talk about heart health in rural areas. Sponsor: Green's Dependable Hardware Russellville, AL

If you're enjoying this interview click this link to join Dr. Ramsey's weekly newsletter and to download free resources: https://drewramseymd.com/free-resources/ Today we are joined by leading expert in the science of sleep, Dr. Marie-Pierre St-Onge, PhD, for a fascinating conversation into how to better optimize your lifestyle and diet for deeper rest. She unpacks some of the common misconceptions vs actual science around sleep. From nutritional supplementation, melatonin optimization, eating windows, and sleep time - we cover it all. She also discusses the importance of learning your body's personal rhythms and creating a consistent ritual around what works best for you. Dr. Ramsey and her discuss the nutrition side of things from alcohol, to tryptophan, to carb-craving and caffeine. ==== 0:00 Intro 3:50 Changing Diet to Improve Sleep 8:51 The Foods Necessary for Better Sleep 11:42 Reality of Tryptophan & Best Sources of It 12:43 Why Eggs are a Good Source of Protein  14:55 Melatonin Containing Foods 16:37 Magnesium Supplements vs Foods 18:20 Eating Windows  22:52 Correlation of Food, Alcohol & Dreams  25:27 Making a Ritual Around Sleep 27:39 Research of Sleep & Cardio-metabolic Health  30:00 Should You Really Be Sleeping 8 Hours? 32:12 Sleep-trackers vs Learning Your Body's Rhythms 34:32 How to Know if You Should be Getting More Sleep 35:15 How Caffeine Influences Your Sleep 37:05 Ultra-Processed Foods Disrupting Your Sleep 41:00 Carb-Craving at Night 43:50 Mental Fitness Practices ==== Dr. Marie-Pierre St-Onge, PhD, is a nutritionist and a pioneer in the field of sleep health. The founding director of the Center of Excellence for Sleep and Circadian Research at Columbia University, her cutting-edge research combines her unique expertise on sleep, nutrition, and weight management to address overall health related to sleep. Dr. St-Onge is the recipient of an Outstanding Investigator Award from the NHLBI (National Heart, Lung, and Blood Institute) at the NIH, and she is a Fulbright Scholar as well as a Fellow of the New York Academy of Medicine. She has authored close to 170 peer-reviewed publications and received scientific achievement awards from the American Heart Association and American Society for Clinical Nutrition. Born and educated in Canada, Dr. St-Onge lives with her family in New Jersey. ==== Connect with Dr. Drew Ramsey: Instagram: https://www.instagram.com/drewramseymd/ Website: https://drewramseymd.com

drdaltonsmith.com Staying Busy is Easy. Staying Well Rested and Avoiding Burnout— Now There's a Challenge. We are a society that praises being busy, the more that one can cram into a day and the fewer hours you need to sleep the more productive and successful you seem, but are you and at what cost? According to the National Heart, Lung and Blood Institute, NIH (June 7, 2017) "Sleep plays an important role in your physical health. For example, sleep is involved in healing and repair of your heart and blood vessels. Ongoing sleep deficiency is linked to an increased risk of heart disease, kidney disease, high blood pressure, diabetes, and stroke." How can you keep your energy, happiness, creativity, and relationships fresh and thriving in the midst of never-ending family demands, career pressures, the stress of everyday life, and Burnout? In Sacred Rest: Recover Your Life, Renew Your Energy, Restore Your Sanity, Dr. Saundra Dalton-Smith, a board-certified internal medicine doctor, reveals why rest can no longer remain optional. Dr. Dalton-Smith shares seven types of rest she has found lacking in the lives of those she encounters in her clinical practice and research-physical, mental, spiritual, emotional, sensory, social, creative-and why a deficiency in any one of these types of rest can have unfavorable effects on your health, happiness, relationships, creativity, and productivity. In Sacred Rest: Recover Your Life, Renew Your Energy, Restore Your Sanity, Dr. Dalton-Smith discusses the seven types of rest using the R-E-S-T method: Recognize your risk Evaluate your current position Science and research Today's application Sacred Rest: Recover Your Life, Renew Your Energy, Restore Your Sanity combines the science of rest, the spirituality of rest, the gifts of rest, and the resulting fruit of rest. It shows rest as something sacred, valuable, and worthy of our respect. SACRED REST gives the weary permission to embrace rest, set boundaries, and seek sanctuary without any guilt, shame, or fear. Media Highlights Sacred Rest Suggested Interview Questions Rest seems like a simple process. Why then do so many people struggle with fatigue, Insomina, and Burnout? What is the distinction between sleep and rest and how does it connect with Burnout? In your book Sacred Rest, you describe seven types of rest. What are they? We can get a sense of what these are just from the names, but to gain a better understanding, can you briefly define each type of rest? When you mentioned emotional rest, you said that it's when you no longer feel the need to perform. Can you say more about this? Your book has lots of teaching stories in it. Do you have a favorite? What are the long-term effects of focusing only on work and omitting regular periods of rest? Is this when burnout happens? What effect does work environment have on rest and burnout? Give us some examples of ways we can add rest in the middle of a busy work day? In the book you mention the gifts of rest, what's does that mean? You offer a unique resource for your readers called “The Rest Quiz”. Can you talk a bit about “The Rest Quiz”? Many people think of rest as a luxury. What would you say to them? Sample TV Segment Focused Questions (3-5 minutes) Rest seems like a simple process. Why then do so many people struggle with fatigue and insomnia? In your book Sacred Rest, you describe seven types of rest. What are they?

Dr. Cynthia "Cindy" Dunbar is National Institutes of Health (NIH) Distinguished Investigator and Chief of the Translational Stem Cell Biology Branch at the National Heart, Lung, and Blood Institute of the NIH. She talks about using macaques to study hematopoiesis and aging, and the challenges and considerations for using these models. She also discusses her collaborative study transplanting iPSC-derived cardiomyocytes into rhesus macaques, as well as the NIH's unique research environment and her musical talents outside of the lab.

Ryan Gorman hosts an iHeartRadio nationwide special featuring John Drikell Hopkins, founding member of the Zac Brown Band, who joins the show to discuss his fight to find a cure for ALS through his Hop on a Cure foundation. Also, Dr. Courtney Fitzhugh, Sickle Cell Disease Expert with the National Heart, Lung & Blood Institute, checks in for Sickle Cell Awareness Month to explain the disease, its impact on life, and the latest treatments. Finally, Dr. Christine M. Crawford, Child Psychiatrist & NAMI Associate Medical Director, discusses rising concerns of parents and caregivers who are struggling to navigate children's mental health.

In this compelling episode of The Healthy Project Podcast, host Corey Dion Lewis welcomes Dr. Alison Brown, a distinguished public health nutrition and health disparities researcher. Dr. Brown shares her extensive insights into the critical intersection of nutrition, cultural humility, and health disparities. Here's what you can expect from this enlightening discussion:Show Notes:In this compelling episode of The Healthy Project Podcast, host Corey Dion Lewis welcomes Dr. Alison Brown, a distinguished public health nutrition and health disparities researcher. Dr. Brown shares her extensive insights into the critical intersection of nutrition, cultural humility, and health disparities. Here's what you can expect from this enlightening discussion:Introduction to Dr. Alison Brown: Learn about Dr. Brown's role at the NIH's National Heart, Lung, and Blood Institute, her background in nutrition and health disparities, and what drives her dedication to addressing diet-related diseases.Cultural Humility vs. Cultural Competency: Dr. Brown discusses the importance of cultural humility in understanding and respecting diverse nutritional practices and why it's more appropriate than cultural competency in health care and research.The Impact of Culture on Nutrition: Discover how cultural background influences dietary choices, the significance of culturally appropriate food access, and the challenges faced by communities in maintaining their dietary traditions in the face of health issues like hypertension and diabetes.Food Insecurity and Nutrition Security: A deep dive into the definitions, impacts, and the importance of culturally relevant solutions to food insecurity, especially in the wake of the COVID-19 pandemic.Addressing Health Disparities: Dr. Brown elaborates on the social determinants of health, including the historic and ongoing challenges of food apartheid, and the need for a multisectoral approach to improve nutrition and health outcomes.Innovative Programs and Solutions: Insight into the "food is medicine" movement, including produce prescription programs and medically tailored meals, and the potential for these initiatives to address dietary disparities with culturally appropriate interventions.Optimism for the Future: Despite the daunting challenges, Dr. Brown shares her hope for the future, emphasizing grassroots efforts, community partnerships, and the critical role of the younger generation in transforming the landscape of public health nutrition.Resources and Recommendations: Dr. Brown highlights valuable resources such as the DASH eating plan and other NIH initiatives aimed at promoting healthier eating habits.This episode is a must-listen for anyone interested in the intricate layers of nutrition, cultural understanding, and health equity. Join us as Dr. Alison Brown offers invaluable perspectives and actionable advice for embracing cultural diversity in the pursuit of healthier communities.Connect with Dr. Alison Brown:LinkedinClosing Thoughts: Corey Dion Lewis wraps up the episode with reflections on the conversation's highlights and a reminder of the importance of culturally informed approaches to health and nutrition.Don't miss this insightful episode of The Healthy Project Podcast, where we explore the power of nutrition and cultural understanding in building a healthier, more equitable world. ★ Support this podcast ★

Hearing loss affects roughly 15.5% of Americans 20 years and older. While the majority of these individuals experience mild hearing loss, the prevalence and severity of hearing loss increases with age. What does this sensory change mean for dementia risk, and can this risk be prevented through interventions like hearing aids? Dr. Frank Lin joins the podcast to discuss the relationship between hearing loss and dementia and share findings from the Aging and Cognitive Health Evaluation in Elders, or ACHIEVE, study. Guest: Frank Lin, MD, PhD, director, Cochlear Center for Hearing and Public Health, Professor of Otolaryngology, Medicine, Mental Health, and Epidemiology, Johns Hopkins University Show Notes Read more about Dr. Lin's study, “Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial,”  in The Lancet. Learn more about the Atherosclerosis Risk in Communities (ARIC) study, mentioned at 20:01, through the National Heart, Lung, and Blood Institute and Johns Hopkins Bloomberg School of Public Health's websites. Read more about U.S. regulations surrounding over-the-counter hearing aids, mentioned at 34:00, in “‘A New Frontier' for Hearing Aids,” by The New York Times. Learn more about Dr. Lin at his bio on the Johns Hopkins Bloomberg School of Public Health website. Learn more about the ACHIEVE study on their webpage. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

Health technology performance and integration of electronic health record (EHR) systems—the creation of interfaces between EHRs and reference labs performing biomarker testing— have become critical factors in conducting efficient and equitable biomarker testing at cancer programs nationwide. At ACCC's 40th Annual National Oncology Conference, an exclusive EHR Working Summit was held to understand barriers to integrating biomarker testing into EHR systems and explore effective practices/workaround solutions to facilitate timely and comprehensive biomarker testing. In this episode, CANCER BUZZ speaks with Karen Huelsman, MS, LGC, precision oncology lead and genetic counselor at TriHealth Cancer and Blood Institute, who also serves on ACCC's EHR Integration program Advisory Committee, about key takeaways and insights from the Working Summit.  “Some of the key barriers include limited staffing on information systems and technical teams—that's the number one ingredient—[also] funding is an important element, having enough FTEs [full-time employees] to create a team, having knowledgeable data engineers and project coordinators…and trying to include some level of clinical input for any new integration implementation team is really important, and those are not always available…” – Karen Huelsman, MS, LGC Guest:         Karen Huelsman, MS, LGC Precision Oncology Lead, Genetic Counselor TriHealth Cancer and Blood Institute Cincinnati, Ohio This episode was developed in connection with the ACCC education program EHR Integration: Effective Practices to Facilitate Timely and Comprehensive Biomarker Testing. This educational program is made possible with support by AstraZeneca and Genentech. Additional Reading/Sources EHR Integration: Effective Practices to Facilitate Timely and Comprehensive Biomarker Testing EHR Integration Landscape Analysis

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/nhlbi-cystic-fibrosis  Overview: “Cystic Fibrosis: The Primary care Provider's Role in Case Finding and Referral” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. Marrah Lachowicz-Scroggins, Program Director with NHLBI's Division of Lung Diseases, and Dr. Deepika Polineni, director of the Cystic Fibrosis Center, Washington University School of Medicine in St. Louis. We'll be discussing what general practitioners should know about cystic fibrosis, including the factors that contribute to delayed or missed diagnosis, and the similarities and differences with primary ciliary dyskinesia, or PCD. 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/nhlbi-sarcoidosis-in-lungs   Overview: “Sarcoidosis in the Lungs: What Primary Care Providers Should Know” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. George Mensah, Director of the NHLBI Center for Translation Research and Implementation Science, and Dr. Mridu Gulati, Associate Professor of Medicine at Yale School of Medicine. We'll be discussing what general practitioners should know about sarcoidosis, including the risk factors, symptoms, challenges in diagnosis, and how sarcoidosis is treated.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/nhlbi-breathe-better-pulmonary-fibrosis   Overview: “Pulmonary Fibrosis: What Primary Care Providers Need to Know” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. Matt Craig, Chief of the Lung Biology and Disease Branch with NHLBI's Division of Lung Diseases, and Dr. Fernando J. Martinez, Chief of the Pulmonary and Critical Care Medicine Division at Weill Cornell Medicine. Today we'll be discussing pulmonary fibrosis and the role of primary care providers, including signs to look out for, diagnosis, and treatment options.

In this episode we discuss a case scenario of Asthma exacerbation. This can be one of the most challenging patients to manage on the ventilator. If at all possible we try not to intubate these patients, however there are times when this happens. We will discuss clinical treatment, ventilator management, and what our rolls are as transport clinicians in the transport of these patients. References: 1) National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 19, 2018).2) McFadden ER Jr, Lyons HA. Arterial-blood gas tension in asthma. N Engl J Med. 1968 May 9;278(19):1027-32. doi: 10.1056/NEJM196805092781901. PMID: 5644962.3) Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. www.ginasthma.org (Accessed on February 13, 2022)4) National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 19, 2018).5) Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001;(1):CD002178. doi: 10.1002/14651858.CD002178. PMID: 11279756.6) Menzies-Gow A, Busse WW, Castro M, Jackson DJ. Prevention and Treatment of Asthma Exacerbations in Adults. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2578-2586. doi: 10.1016/j.jaip.2021.05.016. PMID: 34246434.7) Nanchal R, Kumar G, Majumdar T, et al. Utilization of mechanical ventilation for asthma exacerbations: analysis of a national database. Respir Care 2014; 59:644.

Cancer Support & Dreams   Guest: Chaplain Clara Annunziata Harris Show description: Chaplain Clara Annunziata Harris leads a California Cancer Support Group at the Classic Club in the Palm Desert, California area that meets on the 2nd Saturday of each month. Chaplain Clara is here to share the positive aspects of gathering together to share dreams, emotions, comradery, gratitude, and the healing-power of our Higher Power. Bio: Chaplain Clara Annunziata Harris wears many hats. She leads a Cancer Support Group, is a spiritual counselor, and shared her spiritual gifts at the Betty Ford Cancer Center. Clara Annunziata Harris began her career working in Illinois at the Joliet Diocese. She helped to build St. Daniel the Prophet parish in Wheaton, Illinois, with her Pastor Fr. White, and other talented people on their team. There she began facilitating support groups. Among them were for Women dealing with cancer, Bereavement groups for the young, and another for mature people. Caregivers continued to be the most essential group.    She developed many other areas while going through her CPE education,   including working with cancer patients in hospice. She moved to California in 1995. Her first job was as a Spiritual Care Counselor at the Betty Ford Center. The Cancer and Blood Institute later hired her to continue doing support groups, dealing with patients daily there and in the hospital, as well as home visits. She did support groups weekly, including Women dealing with Cancer, Men dealing with Cancer, Bereavement, and a major Caregiving group. She also facilitated cancer groups for Doctors outside of this practice. In her "retirement," she continues to facilitate cancer support and individual people in need of support.  Video Version: https://youtu.be/jWJPXKMXJ_Q Call in and Chat with Kat during Live Show with Video Stream: Call 646-558-8656 ID: 8836953587 press #.  To Ask a Question press *9 to raise your hand or write a question on YouTube during Show Have a Question for the Show? Go to Facebook– Dreams that Can Save Your Life Facebook Professional–Kathleen O'Keefe-Kanavos http://kathleenokeefekanavos.com/

High blood pressure and cholesterol are commonly seen to signal increased risk of heart disease. To lower both, eating less animal fats, like butter, lard, and tallow, is often recommended. Many of us have the standard LDL, aka “bad” cholesterol or low density lipoproteins, level test done. However, this has shown to only be able to accurately predict heart disease risk around 40 percent of the time. So, is having a LDL cholesterol level on its own really so bad? What kind of test can give a more accurate, say 70 percent, prediction rate for heart disease? Dietary Approaches to Stop Hypertension (DASH), a diet promoted by the HHS's National Heart, Lung and Blood Institute, suggests eating vegetable oils over animal fats to lower LDL cholesterol level. But which type of food may be much worse for our blood cholesterol and heart health? Join Brendon Fallon on #VitalSigns to probe a better way gauge heart-disease risk, whether the DASH diet works, and simple and effective ways to lower blood pressure. ⭕️ Watch in-depth videos based on Truth & Tradition at Epoch TV

Heart disease remains the global leading cause of death for both men and women, but women have long been underrepresented in cardiovascular disease research. We talk to Dr. Susanna Mak, who is aiming to help close that research gap with a study at Toronto's Mount Sinai Hospital; and Dr. Véronique Roger, a cardiologist and senior investigator with the National Heart, Lung, and Blood Institute.

On this episode of Inside Health Care, we offer two interviews. NYC Health + Hospitals leaders, Dr. Eric Wei and Dr. Ted Long, discuss hospital worker burnout, including suicide, and the need for awareness, mitigation and prevention. After that, Inland Empire Health Plan Chief Quality Officer, Dr. Edward Juhn, talks about “algorithmic bias,” a software-based anomaly that may adversely affect population health metrics that drive research on equity. Both interviews were recorded live at NCQA's inaugural Health Innovation Summit, held in late 2022 in Washington, DC. Later, in our “Fast Facts” segment, we observe American Heart Month, with hints for keeping your heart healthy from NIH's National Heart, Lung and Blood Institute. We also tell you about an NCQA HEDIS measure, Cardiac Rehabilitation, that assesses the percentage of adults 18 and older who attended cardiac rehab after a cardiac event like a heart attack, heart transplant or heart bypass.

Episode 128: Food insecurity and obesity.  Nausheen defines food insecurity, presents some statistics about obesity, and how food insecurity is linked to obesity. She ends her presentation with possible solutions to this problem.Written by Nausheen Hussain, OMS3, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific. Editing by Hector Arreaza, MD.Welcome: You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Arreaza: Hello, my name is Hector Arreaza. I am a family physician, currently practicing and teaching in the Central Valley of California. Today we will talk about an important and growing problem: Food insecurity and its relationship to obesity. I would like to introduce my guest today, Nasheen Hussain.Arreaza: Can you tell me what defines food insecurity? Nausheen: As defined by the U. S. Department of Agriculture (USDA), food insecurity is the limited availability of nutritionally adequate food or the limited access to this food. So, I want you to imagine you are living in a community where the closest grocery store is not within walking distance, you have no reliable access to transportation, and you are surrounded by liquor stores, McDonald's, and Burger King. Now you can see the two parts of that definition: the grocery store with healthy food exists, but it is too far, and you can't get to it. Whereas within walking distance is nonnutritious food. I want to challenge our audience to pay attention to these two concepts in the communities around them.Arreaza: I have noticed a concentration of fast-food places lining certain streets. Now that we understand the concept, do we know if there is a way to quantify or measure food insecurity?  Nausheen: Yes, Dr. Arreaza. So, the term “food swamp” actually describes what you just stated. To answer your question, yes. Food insecurity is actually measured by the USDA by a 6-18 item questionnaire - asking questions such as: Were you worried if food would run out before you got money to buy more? It is conducted as an annual supplement to the Current Population Survey. Arreaza: The Current Population Survey (CPS) is the primary source of labor force statistics for the population of the United States. It is sponsored jointly by the U.S. Census Bureau (bee-uro) and the U.S. Bureau of Labor Statistics (BLS). The CPS is conducted monthly. Nausheen: The 2021 questionnaire identified 12.5% of households in the U. S. as being food insecure. However, this may underestimate the true number of individuals who may be suffering from food insecurity. Arreaza: Screening for food insecurity is not been routinely done in many clinics. Food Insecurity: Preventive Services. An Update for This Topic is In Progress. LAST UPDATED: Jul 24, 2022. So now, let's talk about the connection of this to obesity. What factors in general increase the likelihood of obesity?Nausheen: Sure! Obesity is classified based on a person's body mass index or BMI, which is your weight in kilograms (or pounds) divided by the square of height in meters (or feet). A BMI of 30 or greater is considered to be in the obesity category. Obesity is affected by several factors, such as a person's genetics, level of activity, and a high-calorie diet consisting of low-nutrition food.Arreaza: How does food insecurity play into this? Nausheen: Think back to the example we discussed earlier. If a person is experiencing food insecurity due to a lack of access, they will use what is around them (fast food, 24-hour mart without fresh foods) so they can put food on the table. If it is due to financial inaccessibility, they will choose to, say, go to Jack in the Box for their $5.00 deals. Both of these lead to a diet filled with non-nutritious food. This shouldn't come as a surprise: most people that experience food insecurity are likely to be living in low-income communities. The generalization here is that these communities tend to have fewer parks, and if they are present, there tends to be a lot of litter and a cloud of unsafe space hovering over it. Arreaza: I see what you mean.Nausheen: These people will probably be less likely to go out for walks and take their kids out…leading to a sedentary lifestyle. The last association I see is that of mental health. People who are struggling to find food are likely to have stress due to their circumstances and there is a relationship that has been found between depression and the increased likelihood of developing obesity. As a recap, there are three effects of food insecurity that contribute to obesity: lack of adequate nutrition, lack of physical activity, and poor mental health. Arreaza: So, there are several factors of food insecurity that seem to be making individuals more likely to develop obesity. Why does it matter? Nausheen: Well obesity is the gateway to several other diseases such as diabetes and hypertension, which are known to the medical profession as "silent killer diseases." In short, what we typically refer to as "that person is larger built" can have major adverse effects on health and can substantially reduce a person's longevity and quality of life. If we can understand and reduce risks of developing obesity, we can prevent the onset of the disease and/or prevent the progression to more severe outcomes. To bring this more into perspective, the CDC found that from 2017-2020, 1 in 5 children had obesity and about 2 in 5 adults had obesity, with an overall prevalence of 41.9% in the U.S. Arreaza: Let's talk about possible solutions.Nausheen: I think the best solution to this issue has to be two parts. 1. Increased access to healthy foods. 2. Nutrition education on how foods you put into your body impact your health both now and long term. I work with urban farmers in Pomona, CA as part of a grassroots effort to increase access to nutritious foods. Arreaza: Tell me more about it.Nausheen: The system consists of several small-scale community farms that produce chemical-free, pesticide-free, fresh vegetables and fruits that are sold to the community members at a low price or a “pay what you can, take what you need” basis. I believe replicating this system in other communities is effective because 1. It is important for the people to know and trust where their food is coming from, and 2. People can volunteer to help the community farms thrive which not only allows for the sustainability of efforts but gives them a reason to be outside and be active which helps combat obesity! Arreaza: I believe nutrition education is a key element to combat obesity, but the battle is unfair. I see there needs to be a better effort from our government to control such things as the false advertisement of so-called “healthy foods” and “miracle supplements” that promise the cure of obesity. I feel like there needs to be more control of these vendors and pay for false science. Nausheen: Nutrition education itself is also important so that people understand what nutrients their bodies need, what foods can give it to them, how to cook those foods, and lastly how it all affects their health. This should start from elementary school with short lessons embedded into the school curriculum. Arreaza: Thank you for sharing that. This brings our episode to a close. If you are or if you know someone who is struggling with food insecurity, find some resources in your community such as food banks, Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), and other resources. Nausheen: Find community gardens where you live._______________Conclusion: Now we conclude episode number 128 “Food insecurity and obesity.” Nausheen explained that a lack of access to fresh and healthy foods is linked to increased risk of obesity. Dr. Arreaza called for improved controls for scammers and pseudoscientists that frequently commit fraud to patients who are struggling with obesity.This week we thank Hector Arreaza and Nausheen Hussain. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!_____________________Sources:Hartline-Grafton, H. (2018, April 18). Understanding the connections: Food insecurity and obesity (October 2015). Food Research & Action Center. Retrieved February 5, 2023, from https://frac.org/research/resource-library/understanding-connections-food-insecurity-obesity.U.S. Department of Health and Human Services. (2022, March 24). What are overweight and obesity? National Heart Lung and Blood Institute. Retrieved February 5, 2023, from https://www.nhlbi.nih.gov/health/overweight-and-obesity.Food Security in the U. S. - Measurement. USDA ERS - Measurement. (2022, October 17). Retrieved February 5, 2023, from https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-u-s/measurement.Craven, K., Patil, S. (unknown). Understanding Food Security & Obesity Paradox: A Case Study. Department of Family Medicine, Brody School of Medicine.Blasco BV, García-Jiménez J, Bodoano I, Gutiérrez-Rojas L. Obesity and Depression: Its Prevalence and Influence as a Prognostic Factor: A Systematic Review. Psychiatry Investig. 2020 Aug;17(8):715-724. doi: 10.30773/pi.2020.0099. Epub 2020 Aug 12. PMID: 32777922; PMCID: PMC7449839.Centers for Disease Control and Prevention. (2022, May 17). Childhood obesity facts. Centers for Disease Control and Prevention. Retrieved February 6, 2023, from https://www.cdc.gov/obesity/data/childhood.html.Centers for Disease Control and Prevention. (2022, May 17). Adult obesity facts. Centers for Disease Control and Prevention. Retrieved February 6, 2023, from https://www.cdc.gov/obesity/data/adult.htmlRoyalty-free music used for this episode: “Gushito - Latin Pandora." Downloaded on October 13, 2022, from https://www.videvo.net/ 

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down for an intimate discussion with Tiffany McConathy, nurse practitioner at Genesis Cancer and Blood Institute. Tiffany shares her family's personal hardship of learning their eleven-month-old daughter Nora was diagnosed with embryonal tumor with multilayer rosettes (EMTR), a rare and untreatable form of pediatric brain cancer. Together, Chadi and Tiffany discuss Nora's initial diagnosis, patient journey and the critical importance of dedicating research and resources to rare diseases such as EMTR. For more information, please visit: www.CarisLifeSciences.com

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/copd-patient-cases-reduced-lung-function  Overview: “Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode looking at case studies of patients with reduced lung function, we are joined by Dr. Mihaela Stefan, a Program Officer with NHLBI's Division of Lung Diseases, and Dr. Elizabeth Oelsner, general internist and Irving Assistant Professor of Medicine at Columbia University Department of Medicine Division of General Medicine. We'll be discussing profiles of three patients with reduced lung function, including an asymptomatic smoker, a smoker with respiratory symptoms but without spirometric evidence of COPD, and a COPD patient with history suggestive of AAT deficiency. So let's begin.

What is the DASH diet and why is this dietary pattern promoted by institutions such as the American Heart Association and the National Heart, Lung, and Blood Institute? In this episode, Danielle and Mark discuss why this eating plan was developed and the pros and cons associated with it.If you need help lowering high blood pressure, consider our self study here: https://www.imagonutrition.com/services/p/lowering-high-blood-pressure-self-studyTo submit a question to be answered on a future episode, visit: www.imagonutrition.com/podcast Theme song, Thinkin' Bout Food, courtesy of Happy Pill.

Learn about Ryan Olson and Brad Wipfli's Oregon Healthy Workforce Center research. They discuss how their Total Worker Health interventions have helped decrease sedentary behavior (sitting time) and increase physical activity in the workplace. Dr. Olson shares insight into studying team truck drivers in the Tech4Rest study and Dr. Wipfli shares his research studying call center workers in the Active Workplace study. Dr. Ryan Olson is a behavioral and occupational health psychologist who specializes in safety and health interventions for isolated workers, such as truck drivers and home care workers. Ryan is the Co-Director of the Oregon Healthy Workforce Center, a NIOSH Center of Excellence in Total Worker Health®. He also leads an Internationally recognized research program, funded by the National Heart Lung and Blood Institute, that is focused on the safety, health and well-being of commercial drivers.   Dr. Brad Wipfli is an Associate Professor and Assistant Dean of Graduate Academic Affairs in the OHSU-PSU School of Public Health. Brad's research concentrates on health promotion and health behavior, particularly on  identifying strategies to increase physical activity and improve physical and mental health. Learn about Dr. Brad Wipfli: https://ohsu-psu-sph.org/faculty-directory/name/brad-wipfli Access the Active Workplace Toolkit: https://www.yourworkpath.com/activeworkplace Learn about Dr. Ryan Olson: https://www.ohsu.edu/people/ryan-b-olson-phd Learn about the Olson Lab: https://www.ohsu.edu/oregon-institute-occupational-health-sciences/ryan-olson-lab Learn about Tech4Rest: https://www.yourworkpath.com/tech4rest --- Episode information: What's Work Got to Do With The Great Resignation? Guests: Ryan Olson, PhD and Brad Wipfli, PhD Host: Helen Schuckers, MPH Edited by: Helen Schuckers, MPH Produced by: Helen Schuckers, MPH and Anjali Rameshbabu, PhD Music by: Sam Greenspan, MPH Connect with us Oregon Institute of Occupational Health Sciences and Oregon Healthy Workforce Center on social media: Twitter: twitter.com/OHSUOccHealth Facebook: www.facebook.com/occhealthsci.ohsu LinkedIn: www.linkedin.com/company/occhealthsci Blog: blogs.ohsu.edu/occupational-health-sciences Community feedback is important to us. If you love our podcast and want to further support our podcast, please consider leaving us a positive review. Thank you!

This week, please join author Judith Hochman, Editorialist Steven Bradley, and Guest Host Mercedes Carnethon as they discuss the article " Survival After Invasive or Conservative Management of Stable Coronary Disease" and editorial “If the Fates Allow: The Zero-Sum Game of ISCHEMIA-EXTEND.” Dr. Greg Hundley: Welcome everyone to our new year 2023, and we are here on this January 3rd edition of Circulation on the Run. I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Peder Myhre: I am Dr. Peder Myhre, Social Media Editor and doctor at the Akershus University Hospital and University of Oslo. Dr. Greg Hundley: Very nice. Well, welcome listeners and this week's feature, ah, very interesting. You know many times patients with stable coronary artery disease, we're seeing a lot in the literature about an invasive strategy versus a conservative strategy. But what happens long term for these patients? What's their prognosis? Well, more to come in the feature discussion. But first, how about we grab a cup of coffee and we discuss some of the other issues in this session. Peder, would you like to go first? Dr. Peder Myhre: Yes, Greg I would love to and the first paper today is very interesting and relates to one of the most important challenges globally, namely climate changes and extreme temperatures. And in this paper, which comes to us from corresponding author, Barrak Alahmad from Harvard Chan School of Public Health in the United States, together with a large international group of authors, investigated the associations between extreme temperatures and cardiovascular cause-specific mortality in 567 cities in 27 countries from 1979 to 2019. Dr. Greg Hundley: Wow Peder, that is a really large comprehensive study. So, how did they perform this analysis? What did they find? Dr. Peder Myhre: So Greg, the investigators collected city-specific daily ambient temperatures from weather stations and analyzed cause-specific cardiovascular mortality and excess deaths in association with extreme hot and extreme cold temperatures. And in total, the analysis included more than 32 million deaths from any cardiovascular cause, which were subdivided into deaths from ischemic heart disease, stroke, heart failure and arrhythmia and at extreme temperature percentiles. And that is defined as heat above the 99th percentile and as cold below the first percentile were associated with a high risk of dying from any cardiovascular cause, ischemic heart disease, stroke and heart failure as compared to the minimum mortality temperature, which is the temperature associated with least mortality. And Greg, across a range of extreme temperatures, hot days above the 97.5 percentile and cold days below the 2.5 percentile accounted for more than two and more than nine excess deaths for every thousand cardiovascular death respectively. And heart failure was associated with the highest excess death proportions from extreme hot and cold days. So Greg, it seems like extreme temperatures really impact the cardiovascular mortality across the globe. Dr. Greg Hundley: Yeah, beautiful description Peder. And I think what was really exciting about that particular article is you had results from 27 countries. Wow, so really quite a global study and very informative. Dr. Peder Myhre: Yes, indeed very impressive. Dr. Greg Hundley: Well, Peder my next study comes to us from the world of preclinical science. And Peder, these investigators led by Professor Jose Luis de la Pompa from CNIC, evaluated two structural cardiac diseases, left ventricular non-compaction and bicuspid aortic valve. And they wanted to determine if those two conditions were caused by a set of inherited heterozygous gene mutations affecting the notch ligand regulator, Mind bomb-1 and co-segregating genes. Dr. Peder Myhre: Okay Greg, so we are looking at mechanisms for non-compaction and bicuspid aortic valve. What did they find? Dr. Greg Hundley: Right Peder, so whole exome sequencing of the left ventricular non-compaction families identified heterozygous missense mutations in five genes co-segregating with E3 ubiquitin protein ligase-1 Mib-1 as well as left ventricular non-compaction. And corresponding mouse models showed that left ventricular non-compaction or bicuspid aortic valve in a notch-sensitized genetic background. Now, also gene profiling showed that increased cardiomyocyte proliferation and defective morphological and metabolic maturation in mouse hearts and human pluripotent stem cell cardiomyopathy. Biochemistry suggested a direct interaction between notch and some of the identified gene products. And so, these data Peder support a shared genetic basis for left ventricular non-compaction and bicuspid aortic valve with Mib-1 notch playing a crucial role. And thus, identification of heterozygous mutations leading to left ventricular non-compaction or bicuspid aortic valve may allow us to expand the genetic testing panel repertoire for better diagnosis and or risk stratification of both of these conditions, left ventricular non-compaction and bicuspid aortic valve. Dr. Peder Myhre: All right, that is really great and novel linking left ventricular non-compaction to bicuspid aortic valve, really great. And now Greg, we're going to go back to clinical science and we're going to talk about lipoprotein(a) or Lp(a). And as you know, elevated Lp(a) is a common risk factor for cardiovascular disease outcomes with unknown mechanisms. And the authors of this next paper coming to us from corresponding author Olli Raitakari from University of Turku in Finland, examined Lp(a)'s potential role in identifying youths who are at increased risk of developing adult atherosclerotic cardiovascular disease, ASCVD. And they did this by measuring Lp(a) in youths nine to 24 years old and linking that to a diagnosis of ASCVD as adults and also linking it to carotid intermediate thickness in the Young Finns Study. And in addition, these results were validated in the Bogalusa Heart Study. Dr. Greg Hundley: Oh, very nice Peder. So, what did they find? Dr. Peder Myhre: So Greg, those who have been exposed to high Lp(a) levels in youth and that was defined as greater than or equal to 30 milligrams per deciliter, had about two times greater risk of developing adult ASCVD compared to non-exposed individuals. In fact, all the following youth risk factors were independently associated with a higher risk. Lp(a), LD, cholesterol, body mass index and smoking all independently associated with ASCVD. And similar findings were made in the validation cohort who were participants with a high Lp(a) had 2.5 times greater risk of developing adult ASCVD compared to non-exposed individuals. And this also persisted in adjusted models. Now, what about the carotid intermediate thickness? In that analysis, there were no associations detected to youth Lp(a) levels in either of the cohorts. Dr. Greg Hundley: Very nice, Peder. So, great description of the utility of lipoprotein(a) measurements in the youth and for predicting future major cardiovascular events. Well, the next paper goes back to the world of preclinical science. And Peder, cardiac hypertrophy increases demands on protein folding, which causes an accumulation of misfolded proteins in the endoplasmic reticulum. Now, these misfolded proteins can be removed via the adaptive retro-translocation, poly-ubiquitylation and a proteasome mediated degradation process. The endoplasmic reticulum-associated degradation, ERAD, which altogether as a biological process and rate has not been studied in vivo. So, these investigators led by Dr. Christopher Glembotski from University of Arizona College of Medicine, investigated the role of ERAD in a pathophysiological model and they examined the function of the functional initiator of ERAD, VCP-interacting membrane protein and positing that the VCP-interacting membrane protein would be adaptive in pathological cardiac hypertrophy in mice. Dr. Peder Myhre: Thanks Greg. So, we're talking about degradation of the endoplasmatic reticulum and the association to hypertrophy. So, what did these investigators find, Greg? Dr. Greg Hundley: Right, Peder. So, this was really the first study to demonstrate that endoplasmic reticulum-associated protein degradation or ERAD is responsible for degrading and thus, regulating the levels of a cytosolic non-endoplasmic reticular protein. The results reported here describe a new mechanism mediating the pathological growth of the heart, such that in the healthy heart SGK-1 levels are low due to ERAD-mediated degradation. While in the setting of pathology, ERAD-mediated degradation of SGK-1 is disrupted, allowing the pro-growth kinase to accumulate and contribute to pathological cardiac hypertrophy. And so Peder, the clinical relevance of these findings is that the investigators found that a variety of proteins that constitute the ERAD machinery were decreased in both mouse and human heart failure samples while SGK-1 was increased, supporting the possibility that SGK-1 is a contributor to the disease phenotype. And this is notable and that these studies could lead to the development of new therapeutic approaches for managing pathological cardiac hypertrophy and heart failure that target the ERAD to restore efficient SGK-1 degradation. Dr. Peder Myhre: That was an excellent explanation of a very difficult topic. Thank you, Greg. Dr. Greg Hundley: Well, Peder how about we take a look and see what else is in the issue? And now I'll go first. Well, first there's an In Depth by Professor Ntsekhe entitled, "Cardiovascular Disease Among Persons Living with HIV: New Insights into Pathogenesis and Clinical Manifestations within the Global Context." And then, there's a Research Letter by Professor Verma entitled, "Empagliflozin in Black Patients Versus White Patients With Heart Failure: Analysis of EMPEROR results-Pooled." Dr. Peder Myhre: Great Greg and there is an On My Mind by Gabriel Steg entitled, "Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes?" Very timely and interesting. And finally, there is an AHA Update from Michelle Albert, the President of the AHA entitled, "Tackling Adversity and Cardiovascular Health: It is About Time." Dr. Greg Hundley: All right. Well Peder, how about we get onto that feature discussion looking at survival after invasive or conservative management in stable coronary heart disease? Dr. Mercedes Carnethon: Thank you so much for joining us for this episode of Circulation on the Run. I'm Mercedes Carnethon, Professor and Vice Chair of Preventive Medicine at the Northwestern University, Feinberg School of Medicine. And I'm very excited today to have as a guest, Dr. Judith Hochman, who is going to be discussing the long-awaited findings from the ISCHEMIA-EXTEND trial that are looking at survival after invasive or conservative management of stable coronary disease. Really pleased to have you with us today, Judy to hear about these findings. Dr. Judith Hochman: It's a pleasure to be here. Dr. Mercedes Carnethon: Thank you. So, just to start off, can you tell us about this study? What motivated this long-term follow-up of this particular trial? Dr. Judith Hochman: Yeah, so as I think the viewers or the listeners will recall, we built on a wealth of data from COURAGE and BARI 2D, some of the landmark trials that looked at revascularization versus optimal medical therapy or guideline-directed medical therapy alone. We tested an invasive strategy versus a conservative strategy dating back already to 2012 is when we started. And we had a five component primary outcome, which included cardiovascular death, myocardial infarction or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest. And at the end of 3.2 median years of follow-up, we saw no difference in the primary outcome in that the curves crossed with some excess risk upfront due to periprocedural MI and decreased risk of spontaneous MI long-term. But the net overall timeframe spent free of event was similar between the groups. So, we did observe improved quality of life for the invasive strategy, but in terms of clinical outcomes there was no difference. So, cardiovascular death at the end of that time period was no different between the groups, all-cause mortality was no different, non-cardiovascular death, there was actually an increase in the invasive group, which was somewhat of a mystery. We can get into that a little bit later because I think that becomes important. But 3.2 years meeting and follow-up is relatively short. So, everyone was very interested in what would the long-term outcomes be. So, we had another grant from the National Heart, Lung and Blood Institute to follow these patients long-term. And this is an interim report with seven years of follow-up, a median of 5.7 years. And the bottom line is that all-cause mortality was the same at seven years but for the first time, an invasive strategy resulted in lower cardiovascular mortality, which was very interesting and very exciting except that it was offset, exactly offset by the continued excess that we had previously observed in non-cardiovascular mortality. And that's basically the upshot of what we just reported and why we continue to follow patients and why we're going to continue to follow patients and have a final report in 2026. Dr. Mercedes Carnethon: This is really fantastic work. As you point out, the initial follow-up was fairly short and the findings were so critically important demonstrating that there were subtle differences between the two approaches but that overall, things appeared relatively similar. Did it surprise you? Oh, please correct me. Dr. Judith Hochman: I should point out that because there were less spontaneous MIs during follow-up and spontaneous MIs are associated with a heightened risk of subsequent death more so than the periprocedural MIs, we did hypothesize and we're very interested in longer term cardiovascular and all-cause mortality thinking that those reduced spontaneous MIs in the invasive group would be associated with reduced cardiovascular death and perhaps reduced mortality. As I did indicate, cardiovascular death mortality was reduced but all-cause mortality was the same with a hazard ratio of 1.0. Dr. Mercedes Carnethon: Well, nothing seems more clear than a hazard ratio of 1.0 with those very tight confidence limits so thank you so much. I'm really pleased that our editorialist, Dr. Steve Bradley was also able to join us today because to hear his thoughts about where this fits in the context of what we know can be really insightful. So, I'd really love to turn to you, Dr. Bradley. In your opinion, why was this study question so important and tell us a little bit about how you think the clinical field should use these findings. Dr. Steven Bradley: Absolutely and thanks for having me. I think there were some indication that perhaps the farther we follow the patients out from the original ISCHEMIA trial that we might start to see some evidence of benefit for revascularization. I think Dr. Hochman spoke about the evidence of more of these spontaneous myocardial infarctions that were happening in the non-revascularization arm of the study and an association with worse cardiovascular outcomes in patients that experience spontaneous events. And so, the thoughts might be that over time we would see the benefit of that. And certainly if you parse out cardiovascular versus non- cardiovascular outcomes, we do, we see lower rates of cardiovascular death in the patients who undergo revascularization but it's balanced out by non-cardiovascular death. And so, it becomes a zero sum game for a patient. They want to be alive, it doesn't matter by what mechanism. So, if we have a therapy that doesn't actually prolong their life but it leads to different mechanisms by which they have an outcome, that's important for us to understand. This adds to an already robust evidence-based that ISCHEMIA really did inform and it gives us that long-term trajectory to help us understand for patients what the implications are. I will note that and we've commented in the editorial and this is something that was shown in the original ISCHEMIA trial, that it's not just about mortality for patients, it's important that we help them live better as well. And certainly we know that revascularization is associated with quality of life improvement so that's an important part of the conversation with patients. But again, continuing to refine our understanding of what the implications of revascularization are for mortality is where this study leads us now. Dr. Mercedes Carnethon: Thank you so much. One of the things that I find so impressive about clinical trials of this scale are that you incorporate such a broad audience. I note that 36 countries contributed data to this particular trial. I wonder whether, did you have an opportunity to investigate whether these findings were similar in low and middle income countries as compared with higher income countries? And how would you expect clinicians in low and middle income countries to use this information? Dr. Judith Hochman: That's a great question and yes, the treatment effect was similar across regions, didn't really have any very low income regions but we did have India was in the study and a number of South American countries. And I think it's incredibly important for those countries where there are very limited resources to reassure them, the practitioners and their patients that just because they can't afford an expensive invasive procedure, stenting or bypass, does not mean it's going to cut their life shorter, it's not going to make them survive for a shorter amount of time. Therefore, they can limit the use of scarce resources to the most severely impaired in terms of quality of life, the patients with the most frequent angina. It also became extremely relevant during COVID. Dr. Mercedes Carnethon: Tell me more. Dr. Judith Hochman: Well, elective procedures were shut down during COVID and more publications that cited the ISCHEMIA trial to say that they felt comfortable not being able to do elective stenting in patients with stable ischemic heart disease that would've met the ISCHEMIA trial criteria, which by the way we should add was preserved ejection fraction, we excluded ejection fraction less than 35, patients had to be stable. They could not have had two coronary syndrome within the last few months. They could not have had angina refractory to medical therapy and they could not have had left main disease. So, those are key. There are other exclusion criteria but those are the key exclusion criteria. Dr. Mercedes Carnethon: Thank you for that. And I can really see a corollary and I appreciate the messaging around similar outcomes and preserving resources. And I think certainly even within our own country where we see vast differences in access to intensive medical therapies or tertiary care medical centers who do these procedures on a higher volume, at least we can feel reassured that outcomes may be quite similar as far as mortality. What do you- Dr. Judith Hochman: If they take their guideline-directed medical therapy. Dr. Mercedes Carnethon: Thank you for pointing that out. Dr. Judith Hochman: It's incredibly important. John Curtis' group looked at adherent patients by the modified Morisky score versus non-adherent patients. Non-adherent patients don't have as good a health status as adherent patients. So, just that also adds to a wealth of literature that you have much better outcomes if you actually take your medications. Dr. Mercedes Carnethon: No, I think that's a very good point. What are your thoughts, Steve on what the next steps might be? Dr. Steven Bradley: Well, I know that as was pointed out earlier, there's going to be the opportunity to see additional longer term follow-up beyond this interim analysis. So, it'll be interesting to see what that continues to show us in terms of understanding applications on mortality. I'll pose a question that we posed within our editorial around trying to identify non-fatal outcomes to see if there are any opportunity to capture those non-fatal outcomes to give us an understanding of potential mechanisms for why there is this cardiovascular versus non- cardiovascular mortality difference by treatment arm? Certainly, that may be helpful. Dr. Judith Hochman: Sorry. We're very, very interested in the excess in non-cardiovascular death. So, we are as a result of this interim analysis, revising our case report form, which was very lean, pragmatic because the funding is relatively limited to include especially collection of data around malignancy. Because as we reported before, the non-cardiovascular deaths were largely malignancy and to some extent infection. And what was driving the difference, the excess in non-cardiovascular death as we published in American Heart Journal in the invasive group was excess malignancy. Dr. Mercedes Carnethon: That's really interesting. Dr. Judith Hochman: To our deep surprise and shock, it appeared that the only variable associated with that excess risk was the number of tests or procedures you had that involve radiation. And of course, we're talking about medical doses of radiation. And this short timeframe, three and a half to seven years, which is when the curve started to diverge to three and a half, we filed to seven years is not thought to ... it's thought to be too short a timeframe for exposure to radiation to lead to excess malignancy. So, we have partnered with some radiation experts, we are adding much more details to our case report form, not only in terms of death from malignancy but just the occurrence of malignancy. Did you get malignancy during the course of follow-up? And that's really critically important. We are not adding information about additional myocardial infarctions. We think that the key, if we're going to focus on site burden and how much they can actually collect, is to look at the mechanisms of death and the occurrence of malignancy, whether that leads to death or not, those are our top priorities at this point. Dr. Mercedes Carnethon: I could go on and on, I'm learning so much speaking with the two of you. And again, that really is the primary goal of our podcast to really have an opportunity to extend beyond what's written in the paper and really hear directly from the authors who led the study to hear your thoughts as well as those of the editorialists on where this is going. I really want to thank you both for the time you've spent today to share with our audience of the Circulation on the Run podcast. Dr. Judith Hochman: You're very welcome. Dr. Steven Bradley: My pleasure. Dr. Mercedes Carnethon: I just want to thank all of our listeners for joining us on this really stimulating discussion today on this episode of Circulation on the Run. Please tune in next week where we will have more exciting discussions like this one. Thank you. Dr. Greg Hundley: This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Rod Passman, MD highlights a new study on wearables for stroke prevention in patients with atrial fibrillation: the Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial. Northwestern University and Johns Hopkins University were recently awarded a $37 million grant by the National Heart, Lung, and Blood Institute to conduct this seven-year trial. The study will use Apple Watches and a specially developed app available on iPhones to create personalized care for each patient.

Welcome to the podcast with Dr. Brendan McCarthy! In this episode we go over the overall struggle and continuous battle with weight loss. Why we aren't losing weight and talking about what doctors aren't doing to help people with that struggle. Dr. Brendan McCarthy founded Protea Medical Center in 2002. While he's been the chief medical officer, Protea has grown and evolved into a dynamic medical center serving the Valley and Central Arizona. A nationally recognized as an expert in hormone replacement therapy, Dr McCarthy s the only instructor in the nation who teaches BioHRT on live patients. Physicians travel to Arizona to take his course and integrate it into their own practices. Besides hormone replacement therapy, Dr. McCarthy has spoken nationally and locally before physicians on topics such as weight loss, infertility, nutritional therapy and more. Thank you for tuning in and don't forget to hit that SUBSCRIBE button! Let us know in the COMMENTS if you have any questions or what you may want Dr. McCarthy to talk about next! Check out Dr. Brendan McCarthy's Book! https://www.amazon.com/Jump-Off-Mood-Swing-Hormones/dp/0999649604 --More Links-- Instagram: www.instagram.com/drbrendanmccarthy TikTok: www.tiktok.com/drbrendanmccarthy Clinic Website: www.protealife.com Cited Links: 1) Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. Journal of consulting and clinical psychology. 1997; 65(1):79–85. • Phelan S, Nallari M, Darroch FE, Wing RR. What do physicians recommend to their overweight and obese patients? Journal of the American Board of Family Medicine : JABFM. 2009; 22(2): 115–122. • Rothman AJ. Toward a theory-based analysis of behavioral maintenance. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2000; 19(1S):64–69.. 2) Ferri, Fred F., ed. Ferri's Clinical Advisor 2022, E-Book. Elsevier Health Sciences, 2021 3) NIH The Practical Guide. 2000 http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: http://circ.ahajournals.org/content/ear/v/2013/11/11/01.cir.0000437739.71477 ee.citation 4) North American Association for the Study of Obesity, et al. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity, 2000. 5) US Food and Drug Administration. "FDA approves new drug treatment for chronic weight management, first since 2014." Washington, DC Center for Drug EvaluationandResearch(2021) 6) Phelan, Sean M., et al. "Impact of weight bias and stigma on quality of care and outcomes for patients with obesity." obesity reviews 16.4 (2015): 319-326.. • Gilbert, P. (1997). The evolution of social attractiveness and its role in shame, humiliation, guilt and therapy. Br. J. Med. Psychol. 70, 113–147. doi: 10.1111/j.2044-8341.1997.tb01893. • Terrizzi Jr, John A., and Natalie J. Shook. "On the origin of shame: Does shame emerge from an evolved disease-avoidance architecture?." Frontiers in Behavioral Neuroscience 14 (2020): 19. • Fessler, D. M. T. (2004). Shame in two cultures: implications for evolutionary approaches. J. Cogn. Cult. 4, 207–262. doi: 10.1163/1568537041725097. • Curtis, V., Aunger, R., and Rabie, T. (2004). Evidence that disgust evolved to protect from risk of disease. Proc. R. Soc. B Biol. Sci. 271, S131–S133. doi: 10.1098/rsbl.2003.0144 • Oaten, M., Stevenson, R., and Case, T. (2009). Disgust as a disease-avoidance mechanism. Psychol. Bull. 135, 303–321. doi: 10.1037/a0014823. • Ananthakumar, Thanusha, et al. "Clinical encounters about obesity: systematic review of patients' perspectives." Clinical obesity 10.1 (2020): e12347..   #weightloss #weightlossjourney #fitness #healthylifestyle #motivation #health #healthylifestyle

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/Podcast/copd-treatment-for-primary-care-providers Overview: “Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode on COPD treatment for primary care providers, we are joined by Dr. Mihaela Stefan, a Program Officer with NHLBI's Division of Lung Diseases, and Dr. MeiLan Han, Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of Michigan. We'll be discussing the range of treatments for patients diagnosed with COPD using spirometry, including lifestyle interventions, pulmonary rehabilitation, medications, and non-medication COPD treatments. 

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/Podcast/identifying-and-testing-for-copd Overview: “Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode on identifying and testing for COPD in primary care, we are joined by Dr. Antonello Punturieri, a Program Officer with NHLBI's Division of Lung Diseases, and Dr. Byron Thomashow, Professor Emeritus at Columbia University Medical Center and Co-founder and Chief Medical Officer of the COPD Foundation. We'll be discussing why primary care providers play such a crucial role in finding COPD cases among patients, the tools to help identify these cases, and the diagnostic criteria that points to starting appropriate treatments. 

The aftermath of the Women's Health Initiative (1990s), left millions of women confused and scared about their risk of developing breast cancer if they used hormone therapy. The science was later debunked due to the study's flaws, but the dark cloud of fear still reigns. Can we undo the damage?October is Breast Cancer Awareness month and I am celebrating my mother, a breast cancer survivor, and all the women (and men) who've battled this terrible disease. In 1991, the National Heart, Lung, and Blood Institute began the largest clinical trial in the US to better understand how these diseases (breast cancer, heart disease, stroke, blood clots), affected post-menopausal women. More than 160,000 women, ages 50-79 participated in this 15-year-long study. In 2002, results found that post-menopausal women taking estrogen and progestin HRT had an increased risk for all of the diseases I listed before. As a result of these findings, millions of women stopped taking hormones, many doctors stopped prescribing these hormones, and the study was halted prematurely. Years later, it was discovered that the study wasn't all that kosher. There were flaws.By the time the flaws were discovered, the damage had already been done. Women, who would have been protected against these diseases, were now suffering from menopausal symptoms, a staggering increase in heart disease (the #1 killer for women post-menopause), hip fractures (in one study I read, there were an estimated 43,000 hip fractures reported each year after the study stopped), and those women are now much too old to begin thinking about HRT, like my mother.Millions of women do not take hormones for fear of developing breast cancer. Their fear stems from either being misinformed or misguided by their doctor or they haven't had the opportunity to talk to their doctor about their options. Meanwhile, they experience night sweats, brain fog, loss of lean muscle mass, increased body fat, low to no libido, hair loss, and don't sleep. At the end of the day, we all get to make our own choices, but let's just make that choice based on education, knowledge, and the current medical science.To help break this all down for us, I have invited an exceptional guest to today's episode. Dr. Jenn Simmons was a breast cancer surgeon and a leader in cancer care in Philadelphia. After spending 17 years as Philly's top breast surgeon, her own illness led her to discover functional medicine. In 2019, she left her esteemed surgical position for a new life as a functional medicine doctor and founded Real Health MD with the mission to help women with breast cancer truly heal. Dr. Jenn believes that we all have the ability to live healthy and productive lives. Her integrative approach takes into account your physical, mental, emotional, spiritual, and social well-being.Medical Disclaimer:By listening to this podcast, you agree not to use this podcast as medical advice or for making any lifestyle changes to treat any medical condition in either yourself or others. Consult your own physician for any medical issues that you may be having. This entire disclaimer also applies to any of my guests on my podcast.Find Dr. Jenn here:website: www.realhealthmd.comFB: RealHealth MDIG: drjennsimmonstwitter: Dr. Jenn SimmonsRegister now for Beyond The Cancer Summit:https://bit.ly/3HnYp1f

The aftermath of the Women's Health Initiative (1990s), left millions of women confused and scared about their risk of developing breast cancer if they used hormone therapy. The science was later debunked due to the study's flaws, but the dark cloud of fear still reigns. Can we undo the damage?October is Breast Cancer Awareness month and I am celebrating my mother, a breast cancer survivor, and all the women (and men) who've battled this terrible disease. In 1991, the National Heart, Lung, and Blood Institute began the largest clinical trial in the US to better understand how these diseases (breast cancer, heart disease, stroke, blood clots), affected post-menopausal women. More than 160,000 women, ages 50-79 participated in this 15-year-long study. In 2002, results found that post-menopausal women taking estrogen and progestin HRT had an increased risk for all of the diseases I listed before. As a result of these findings, millions of women stopped taking hormones, many doctors stopped prescribing these hormones, and the study was halted prematurely. Years later, it was discovered that the study wasn't all that kosher. There were flaws.By the time the flaws were discovered, the damage had already been done. Women, who would have been protected against these diseases, were now suffering from menopausal symptoms, a staggering increase in heart disease (the #1 killer for women post-menopause), hip fractures (in one study I read, there were an estimated 43,000 hip fractures reported each year after the study stopped), and those women are now much too old to begin thinking about HRT, like my mother.Millions of women do not take hormones for fear of developing breast cancer. Their fear stems from either being misinformed or misguided by their doctor or they haven't had the opportunity to talk to their doctor about their options. Meanwhile, they experience night sweats, brain fog, loss of lean muscle mass, increased body fat, low to no libido, hair loss, and don't sleep. At the end of the day, we all get to make our own choices, but let's just make that choice based on education, knowledge, and the current medical science.To help break this all down for us, I have invited an exceptional guest to today's episode. Dr. Jenn Simmons was a breast cancer surgeon and a leader in cancer care in Philadelphia. After spending 17 years as Philly's top breast surgeon, her own illness led her to discover functional medicine. In 2019, she left her esteemed surgical position for a new life as a functional medicine doctor and founded Real Health MD with the mission to help women with breast cancer truly heal. Dr. Jenn believes that we all have the ability to live healthy and productive lives. Her integrative approach takes into account your physical, mental, emotional, spiritual, and social well-being.Medical Disclaimer:By listening to this podcast, you agree not to use this podcast as medical advice or for making any lifestyle changes to treat any medical condition in either yourself or others. Consult your own physician for any medical issues that you may be having. This entire disclaimer also applies to any of my guests on my podcast.Find Dr. Jenn here:website: www.realhealthmd.comFB: RealHealth MDIG: drjennsimmonstwitter: Dr. Jenn SimmonsRegister now for Beyond The Cancer Summit:https://bit.ly/3HnYp1f

Data shows that greater gender diversity on company leadership groups leads to improved business outcomes, says Stanford cardiologist Hannah Valantine. Likewise, she says, in medical research, where diversity boosts the development of new technologies.In this episode of Stanford Engineering's The Future of Everything, Valantine, the former inaugural chief officer for scientific workforce diversity at the National Institutes of Health, as well as a senior investigator at the National Heart, Lung, and Blood Institute, discusses why increasing the diversity of researchers and study participants is vital to medical innovation. Valantine and host, bioengineer Russ Altman, then explore the barriers that keep new medical technologies, such as a blood test to detect signs of heart transplant rejection, from being used in hospitals. Listen and subscribe here.

The Future of Everything with Russ Altman: E188 | A cardiologist says embracing diversity will catalyze medical research Diversity in medicine boosts innovation and has even improved physicians' ability to prevent transplant rejection. Data shows that greater gender diversity on company leadership groups leads to improved business outcomes, says Stanford cardiologist Hannah Valantine. Likewise, she says, in medical research, where diversity boosts the development of new technologies. In this episode of Stanford Engineering's The Future of Everything, Valantine, the former inaugural chief officer for scientific workforce diversity at the National Institutes of Health, as well as a senior investigator at the National Heart, Lung, and Blood Institute, discusses why increasing the diversity of researchers and study participants is vital to medical innovation. Valantine and host, bioengineer Russ Altman, then explore the barriers that keep new medical technologies, such as a blood test to detect signs of heart transplant rejection, from being used in hospitals. Listen and subscribe here.

On this episode I chatted with translate patient Ron Black about his experience with OBI that saved his life. Ron grew up in Seattle and joined the navy. After being honorable discharged he found his way to Oklahoma.  Arriving in Oklahoma Ron developed a love for hunting joining his already passionate energy for politics he dove into tv broadcasting with his hunting show and found his way onto the radio with his own three hour drive home show. So yes, I was bring judged on my radio interview skills by a master of the decks! Ron suffered some health scares and found himself on the operating table waiting for a new liver. His transplant took a lot longer than usual and without the blood donations of Oklahoma donors he would simply not be here today. Like he says in this podcast he wouldn't be walking his daughters down the isle this year.  Once he was cleared to work by his doctor he applied for a job with OBI and his now raising awareness about the blood donations that save Oklahoma lives.  For more information on OBI go to www.obi.org Contact them here www.obi.org/contact/ This episode is presented by the Oklahoma Hall of Fame, telling Oklahoma's stories through its people since 1927. For more information on the Oklahoma Hall of Fame go to www.oklahomahof.com and follow them on instagram for daily updates at www.instagram.com/oklahomahof  #thisisoklahoma   

In Episode 64 of the Sarc Fighter podcast Mary McGowan, CEO of the Foundation for Sarcoidosis Research and Tricha Shivas, Chief Strategy Officer talk about an exciting new development that will make it easier to patients to find the right doctor, and for doctors to find the right methods to treat Sarcoidosis.    Show notes The New FSR Initiative https://www.stopsarcoidosis.org/foundation-for-sarcoidosis-research-launches-groundbreaking-global-rare-disease-initiative/ Learn about the clinical trial from Novartis: https://bit.ly/3o9LXKk The FSR Summit: https://www.stopsarcoidosis.org/events/fsrs-third-annual-virtual-sarcoidosis-education-summit-unveiling-possibilities/ The Mayo Clinic article: https://www.mayoclinic.org/healthy-lifestyle/stress-management/in-depth/how-to-be-happy/art-20045714 Calvin Harris Blog: https://sarcoidosisnews.com/2022/05/19/im-grateful-that-despite-sacroidosis-i-can-run-my-own-race/ aTyr Pharma News Release: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-presents-clinical-data-efzofitimod-atyr1923-american Merlin: https://merlin.allaboutbirds.org/ Universal Barriers Podcast:  https://www.stopsarcoidosis.org/sarc-fighter-podcast/ More on Universal Barriers https://www.stopsarcoidosis.org/events/universal-barriers-in-dealing-with-a-chronic-disease-a-sarcoidosis-perspective/ Ignore No More https://www.stopsarcoidosis.org/ignore-no-more-foundation-for-sarcoidosis-research-launches-african-american-women-sarcoidosis-campaign/ Sarcoidosis Awareness Film: https://www.purpledocumentary.com/ Nourish by Lindsey: https://www.nourishbylindsey.com/ Dr. Jinny Tavee's book, The Last Day of Suffering: https://www.amazon.com/Last-Day-Suffering-Health-Happiness/dp/0615542751 Read about the patient trial with aTyr 1923 https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-positive-data-phase-1b2a-clinical-trial Also -- Note that investors also believe in the promise of aTyr 1923: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-closing-863-million-public-offering Yale University and sarcoidosis skin treatment | Dr. William Damsky: https://news.yale.edu/2018/12/26/yale-experts-treat-severe-disfiguring-sarcoidosis-novel-therapy Stanford University Clinical trial | Dr. Mathew Baker: https://med.stanford.edu/sarcoidosis/clinical-trial.html MORE FROM JOHN Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Watch the Prednisone Town Hall on YouTube https://youtu.be/dNwbcBIyQhE More on aTyr Pharma: https://www.atyrpharma.com/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com   The following is an Internet generated transcript of the interview.  Please excuse spelling and grammatical errors. John Carlin: welcome back to the Sarc Fighter podcast. I am so pleased today to have the people that make FSR absolutely run and operate here as guests today to talk about this new initiative. Our CEO, uh, Mary McGowan and Chief Strategy Officer Tricia Chivas are both here. Welcome to the podcast. Mary McGowan: Thank you, John. It's always a pleasure to be a guest on your podcast. Tricha Chivas: Thanks so much, John. We're excited to talk to you today. John Carlin: So the email went out this week, and we're talking late June. In 2022, FSR has a new program that deals with how FSR will be recognizing endorsing recommending clinics. Mary, tell me how all that works and tell me the gist of this new announcement. Mary McGowan: John, we're so excited this, week to have announced publicly this really exciting new initiative called the FSR Global Sarcodosis Clinic Alliance. The whole concept of this is to bring hospitals and Sarcodosis clinics together globally in the fight against Sarcodosis. So we were thrilled the very first presentation that we did was in March. We were, uh, hoping to launch this in January, but due to COVID, we couldn't for, um, obvious reasons, because the clinics were so engaged in taking care of COVID patients. And in relatively very short period of time, we are so thrilled that we had 22 esteemed founding members join us as they learned about this. Um, and we're continuing to accept founding, uh, members through September to continue to grow this and work with them as part of a leadership council. And, um, so anyway, this all developed because we, uh, saw this opportunity to be able to connect more closely with Sarcodosis clinics and hospitals. And after we had the vision for this, we actually sent out a survey to clinicians across the globe. Uh, and they, too, verified this opportunity and this need for bringing us all together to share best practices and to network both at the clinician and patient level. And that is why, uh, we decided to move forward with this extraordinary rare disease initiative. John Carlin: Yeah, that is a lot, and there's so many things I want to unbundle here. But let's start with what are the ways that patients will be supported by this alliance? If I've got psychodosis, how does this help me? Mary McGowan: Well, we want to ensure in every community across the globe that Sarcoidosis patients have access to the most up to date, uh, Sarcodosis information, education and support services. So what we're going to do is, through, uh, an application process, we're going to have Sarcoidosis patients apply to be peer led support group leaders. And we're going to host support group meetings monthly, uh, at institutions throughout the globe. In addition to that, some of the, uh, volunteers will receive training on how to be community educators and how to work with the media so that we can amplify, uh, the messaging about Sarcodosis about this rare disease throughout local communities, again, around the globe. So we're really excited to be recruiting for these leadership positions, and we're, uh, going to have ongoing trainings that are going to support these leaders and also provide opportunities for these leaders to network with each other. In other words, the, uh, other leaders across the globe in this effort to, uh, be able to provide these kinds of support services to patients. John Carlin: So these leaders will be patients? Mary McGowan: Yes, these leaders will be patients. We believe very strongly at FSR in the peer led leadership approach because it's, uh, really the patients who have the best understanding of what it's like living with Sarcodosis. And if we can empower them to, uh, be leaders of the support group sessions, then we believe that that has the strongest impact. John Carlin: And do you foresee in a post covered world of these support groups would meet in person? Mary McGowan: Yes, we do hope that they will be meeting shortly in person as the, uh, world hopefully continues to try to get back to normal and as we, uh, continue to fight Cobid and its forces, we do hope to have these in person. And up until the point when they can't be in person, we will be doing these virtually. John Carlin: And you did ring one of my bells when you said media training, how to deal with the media. Mary McGowan: Yes. John Carlin: Maybe I can help you with that. Mary McGowan: We, uh, would love that, John, of course, because, uh, we want to make sure that our volunteer leaders feel comfortable working with the media and, uh, have an opportunity, uh, to rehearse their talking points and again, empowering them so that they can empower others in their local communities. John Carlin: Got you. So there's 22 of these centers. That is center the right word? We're going to call somebody who's one of the 22. Mary McGowan: We're calling them founding members of the FSR, uh, Global Clinic Alliance. John Carlin: Alliance. Alliance members. Alliance members. Got it. And there's 22 alliance members. But that's all around the world right now, as you and I are speaking on June 24, 2022. Mary McGowan: Yeah. So right now, the 24 that have joined are from the United States. We are, uh, doing a webinar in July to invite all clinics globally, from around the world to the webinar about the alliance. And we're hoping, uh, at that point, that we will then have an opportunity to introduce this to International Sarcodosis, uh, Clinic Alliance potential members and have them join also as a founding member, I. John Carlin: Know because I've talked to so many doctors in other parts of the world through the podcast that FSR has got a long reach. So I don't anticipate that. I think, uh, it's going to be very popular in other parts of the world. Mary McGowan: We agree. And we're very excited to be working with our International Clinic, uh, future, uh, members. John Carlin: Right. I got you. So now, we talked a little bit about the patient side, but this has a big upside for the doctors, the researchers, the clinicians, I guess, is the proper term. Uh, what is the clinician facing program that the alliance offers? Mary McGowan: Well, there are several. I'll highlight a few. First of all, we believe, and we also confirmed again through the survey, that there's a real desire for these clinicians to have an opportunity for peer case review for, uh, cases that they have. Sorkidosis cases. So we're providing a platform for these peer case review sessions so, uh, that the clinicians can share the information and can get guidance, uh, and advice and input from other clinicians at other clinics, uh, worldwide. So that's one, the other one that we're really excited to be launching is a journal club, and we believe, uh, a, uh, Sarcoidosis specific journal club that's going to be supporting early career professionals and also encourages clinicians to stay up to date on Sarcodosis, um, medical literature, uh, is really going to be very effective. And again, an, uh, opportunity to bring these experts in these global clinics together to learn and talk about these journal articles. And then finally, we're also providing clinical, uh, engagement and education through, uh, our Clinic Engagement series. We just held our conference on June 15. We had, uh, I think, nine different countries that were represented over, uh, 100 registrants. And we had Dr. Menza from the NHLBI, who was, uh, the keynote speaker at this, um, really exciting conference. So we're going to be doing these quarterly, uh, and again, it's an opportunity to bring clinics together globally, to stay up to date on research and other topics around orchidosis care, education, research and support. John Carlin: I guess the end goal for all this, because when I'm talking to patients on the podcast, what they're saying is, I go to my local doctor and they've never heard of Sarcoidosis. This would be the beginning of a way to fix that, right? Mary McGowan: Correct. That's our belief as well. We do know, uh, that, again, uh, awareness is large, not only in the general population, so that if an individual does have psychedosis, uh, and has signs and symptoms of Sarchidosis, that they can bring that up to their doctor, hopefully for a shorter time period for an accurate diagnosis. But also to your point, John, from the clinician standpoint, again, there are, uh, so many rare diseases, and we want to make sure that Sarcodosis is front and center with clinicians, uh, and again, for the opportunity, uh, for a more timely, uh, accurate diagnosis, which, of course, can be lifesaving. And this is, um, critically important. And FSR beliefs strongly in making sure that we are working as hard as possible to bring this awareness to clinicians, uh, as well as to patients themselves. John Carlin: Basically, what this is infrastructure that's going to have doctors talking to each other more, sharing their research, sharing their best practices, sharing their success and failure stories, so that more doctors and more places are conversing about Sarcoidosis and understanding best practices, best paths forward, making patients have better outcomes. Mary McGowan: Absolutely. Beautifully said, John. Thank you. John Carlin: Okay. All right, well, that's my job. I like distilling stuff. First, I want to ask you, I know that FSR has been doing, uh, some stuff with the National Institutes of Health, and there really is some momentum now to get some federal backing for some of the things that FSR is doing and for Sarcodosis related research from the government, which we never have had before. Tricha Chivas: Yeah, thanks, John. We've been working really hard to grow relationships with the National Institutes of Health. And one of the ways that we've been doing that is to make sure that we are engaged in different institutes at the National Institutes of Health. So there's a lot of different institutes that have a particular focus. So Mary mentioned earlier that we had a session with Dr. George Menza, um, from the NHLBI, which is the National Heart and Lung and Blood Institute. And that is one of the, uh, areas, um, that has been a big focus for where Sarcodosis has been in the past. But we're also focusing in other areas, such as in the, um, environmental health studies area. So there's an institute that focuses on environmental impact, since we know there may be some environmental causes to Sarcodosis, um, and making sure we're part of that. We've been working with the organization that focuses on arthritis, um, and musculoskeletal disease and skin disease. Right. So we know there's different manifestations of psychosis, and we're having conversations now at all of these different spaces. In fact, this year in February, um, you may recall that FSR was able to participate in the NIH Rare Disease Day by having a panel, um, there. So really kind of activating and showing the NIH again, what we are doing and why the work that we're doing is so critically important in this space. And these are conversations that we're continuing. But in addition to the NH, we've also started working with the FDA on a number of different things in order to draw more attention from that federal level as well. John Carlin: And are we making some progress with respect to this work? Tricha Chivas: Yeah, so very excitingly. We just had a FDA patient listening session, uh, on pulmonary Sarcoidosis. This is a really, um, unique opportunity for FSR to get directly in front of the FDA and many, um, members of the FDA. We had 50 attendees at this session. It was a very well attended session, representing a lot of different institutes at the FDA. And for all of your listeners. I know everybody is a little, um, bit more familiar with the FDA now after cobid, but the FDA approves drugs, but they also, um, approve technologies that are being used for diagnosis. And they also, um, can help with the process, um, for repurposing drugs. So they have a number of different angles that we wanted to highlight that tie into the work and the needs of our patient population. And so what we did was we had this listening, um, session, which is a closed session, we weren't able to have that available to the public. That's the rules of the session itself. And then we had patients that came together, shared their stories. We had six patients, one caregiver. Mary shared a bit about things that we had learned from the community on this. And then, um, Dr. Lisa Meyer, who had provided the clinician perspective. And so that was our, uh, main goal was to get that information out. And these were really passionate stories that reflected what we heard from the community. John Carlin: So what would actually happen in a listening session? The doctors are listening to the patient's talk and see how Sarcidosis affects their lives. Tricha Chivas: Sure. Great question. So basically, it's an hour and a half long, um, meeting, and you have all of these different folks at the FDA who are making decisions about how drugs are approved or how technologies move forward. And we wanted to give them a chance. A lot of them are very scientific and don't necessarily have the chance to truly understand the patient experience. So, um, what this is, is a chance for them to understand how Sarcodosis is impacting individuals daily lives. What were the challenges that people faced with diagnosis, um, where did the technology, um, fail? And why do we need different technologies that might be able to do a better job, to do better at diagnosing? Understanding the drug, um, development process from the patient perspective would have been the barriers or challenges. So we raised issues there about diversity and, um, the challenges for diverse populations to be involved. We raise challenges for the drugs that are currently available, not adequately addressing the needs of, um, those living with Sarcodosis. So steroids is actually FDA approved in Sarcoidosis. And so that is oftentimes, um, a go to, as I know you've talked about many times on the podcast, a go to for clinicians as they're moving forward because it's cheaper there, um, are ways that it does work sometimes for some patients, but the cost was also something we reflected in those stories. So the stories were individual people sharing how all of those different things came to play. John Carlin: Um, if nothing else, Sarcodosis is on the FDA's radar now, right? Tricha Chivas: Yes. John Carlin: There's so many orphan diseases and everybody's clamoring to be recognized, but it sounds like, thanks to the work of FSR, that's happening now. Our voice is a little bit louder, 100%. Tricha Chivas: We are on the, um, radar, and we have some really exciting things that are going to be coming out as a result of that. And Mary, I don't know if you wanted to share some of the things that were coming out as a result of what we did with the listening session. Mary McGowan: Absolutely. So after the listening session took place, we started creating, uh, a white paper that have a little bit more details on the session. And we're going to be launching the white paper in mid July. In addition to that, we're going to be hosting a community webinar in August, because we're so grateful to the community. I think. You know, John, our approach at FSR is always about engaging the community in our efforts. So, in preparation for the FDA patient listening session, we sent a survey to our clinicians, to all of our patients, and to our industry partners, because we wanted to get, uh, what they thought was the important messaging to send to the FDA. And that's how we came up with our messages. That's how we came up with the patients who had those stories that, uh, reflected those messages. And so we want to give back to the community and share the results of the survey and share the details of this really milestone event for FSR that took place. In addition to that, we are, um, also now working on the possibility of hosting a patient focused drug development session sometime later next year. And these sessions are much larger. They are open to the public, and they are important for advancing clinical trials and drug development. So we're really excited about that. And at the same time, we're also exploring conducting additional patient listening sessions and other manifestations, such as neurosychotosis or cardiac sarcoidosis to deepen the FDA's understanding, uh, and needs of those living with this complex disease. John Carlin: Yeah, when you, uh, say neurosark, I'm so happy to hear that. I'm an orphan among orphans as the neurosark representative. So I'm, um, glad that that's getting spotlighted, uh, a little bit. Mary McGowan: Uh, absolutely. John Carlin: Yeah. All right, so now we got clinical trials, and it does seem like there's a lot more going on right now with clinical trials and trisha. Can you bring us up to speed on what's going on with that? I've talked to several different people, and I know there's a bunch of pharmaceutical companies out there, so can you kind of let us know where we are with that? Tricha Chivas: Yeah, 100%. So this is a really exciting time as far as clinical trials goes in sarcodosis. In the past, we've had, um, one clinical trial running at a time, or many times even no clinical trials running in our space. But right now, um, there is a lot of interest and engagement in the clinical, um, trial space. And as you know, SSR has done a lot of background work to try to make sure that this is really possible for pharmaceutical companies to come into this space. So what's important and what we have done is we've made it so that they understand there is an eager population that's interested in clinical trials that wants more and new drugs, and helping to do that education on the back end for them. And then, in addition, we have really worked very closely with pharmaceutical partners, getting them access to, um, some of the key opinion leaders in the space, some of those expert clinicians that are out there so that they could have really good conversations and understand a little bit more about how their drug might work, whether it's a good fit for the clinical practices that they're trying to meet. And then in addition to that, we've worked really closely with the patient, so we know that patients are, um, interested, so we want to make sure we're getting that in front of them. And so we put in place a system that allows for people to know about clinical trials that are going on. So we do a lot of marketing and advertising, um, for that, for patients, so they can get involved if they're interested in being part of that process. And I'm really excited to share with you that we have seven sponsored clinical trials underway right now. And so, remember, I said there was about one or two happening, staggering over in the past. And now, um, we have seven potential clinical trials that are starting off. And just to clarify for your audience very quickly, when we're talking clinical trials here, we're talking pharmaceutical sponsored or biotech sponsored clinical trials, which are the ones which will end up resulting ultimately in a new drug. And so we have the academic studies which are building all the background for that, and they continue. And those are very important, but these are the ones that are getting much closer to getting that new therapy available for patients. John Carlin: Seven. Tricha Chivas: Seven. John Carlin: That's amazing. Just in the time that we've been doing the Stark Fighter podcast, I think, like you said, one or two, and that was reason to celebrate. And now, a couple of years later, it's up to seven, potentially. And that could result in seven new drugs that patients could take. And the farther you can get those of us who are patients away from steroids, the happier we all will be. Tricha Chivas: Exactly. Yeah. So it is a really exciting time. If anybody does want to know more, um, about clinical trials, please reach out to us, how they work. We're happy to give more background information, but this is the moment where we hopefully can get more and more engagement and more excitement around this. And this is why partly, we're talking to the FDA as well, because it's very important for us to continue those conversations. John Carlin: So anything else happening that listeners should know about? Tricha Chivas: Sure, yeah, there's a lot going on in research right now. Um, thank you to everyone who has supported all the research efforts that we have. FSR has been taking our research funding worldwide. You may know that we have funded over, um, $6 million worth of Sarco Dosis specific research efforts. And last year, we gave out about $200,000, uh, in research grants to academic researchers. This year, we're poised to give out over $300,000 in research funding to our academic researchers. And so this is really an exciting time. We just, right now, are in the final wrap up stages for our fellow that's going to be coming out this year. So we have received those applications and are finalizing the announcement, so keep an eye out for that. And very excitingly, we have grants that just came, um, out, uh, specifically for, um, pilot grants, which are early background kind of information studies that can help make it possible for researchers to get bigger funding to move the needle forward, and a new grant, which we have not had up until this point specifically available for cardiac sarcidosis, and we had an incredible amount of engagement around that. John Carlin: Yeah, so let me ask you about that. How excited are the researchers, Mary, uh, for this opportunity? Mary McGowan: Really very exciting, and I think it builds off the momentum that Trisha has been talking about, just about the interest in clinical trials and in research in the sarcodosis space. Again, we received the most applications ever for our pilot grants, and we received a very high number of cardiac sarcodosis grants, by the way, which was made, uh, available through a very generous donor to FSR, and wanted us to be providing funding, uh, specifically for cardiac sarcodosis. So we are so grateful to donors who allow this type of, uh, funding for additional support and research for, uh, sarcodosis. But I think all of this combined, John, is really building on this tremendous momentum for sarcodosis. Again, we see it at the FDA, we see it through the Clinic Alliance, we see it through research, we see it through the patient engagement, and it's just such an exciting time to really be moving the needle forward for sarcoidosis. We have our upcoming Patient Summit, uh, and thank you for your leadership, uh, as part of the Patient Advisory Group. And you all coming up with the title of Unveiling Possibilities Moving forward. And really, this is just what is happening at foundation for Sarcoidosis and for sarcodosis globally. And it's most exciting. John Carlin: Yeah. Tricia, do you want to add anything to that? Tricha Chivas: I don't have much to add, uh, except to say that we are also very, very excited. I know that the, um, conference itself is something we're very excited about. There's a lot of opportunities for us to engage around the conference. If you have not attended, um, an FSR conference, this is virtual, it is available. Last year, we had many individuals from all over the world participating in this. There's opportunities for networking, there are opportunities for engaging with global experts. So, um, whether you're brand new or you've, uh, had sarcodosis for a little bit of awhile, we'll have different tracks that can help you learn a little bit more about what's happening in the disease or what you need to know. And then we also have these great tracks that came out of the wonderful theme that you came up with that's really focused specifically on things, um, like understanding your, um, finances, how to talk to your clinician, how to engage and learn, um, from others when you're trying to navigate the symptoms of your disease kind of life hacks, as it were, in order to think about things. So we're really excited about, um, that coming up and what that conference is going to be when we invite all of you to join us. John Carlin: Yes, the summits are wonderful, and I hope we get back to a point where they're in person again. Hopefully, we, uh, can get the pandemic behind us, and that's just my thought, just thinking, um, out loud, the networking opportunities, I think, are as good as they are virtually. I'm hoping that eventually we um, can all kind of meet in person. Because every time I've been for work to an event, you learned, uh, as much having a beer after the day, sitting around with your fellow conference as you do in the conferences themselves. Mary McGowan: Right? Tricha Chivas: And I think that's one of the things that will be another benefit coming from the Clinic Alliance is that um, opportunity for um, more local level engagement, uh, with others. And that is definitely something we want to be focusing in on as we move things forward there. John Carlin: Got you. So let me shift gears a little bit, Mary. Last year, early this year, there was some really exciting programming, uh, focused on increasing diversity. I was involved in some of that and inclusion with respect to uh, sarca dosis. How will FSR be continuing that work? Mary McGowan: Uh, John, this is such an important area for FSR. We believe so strongly in diversity and inclusion in everything that we do at FSR. But we were so thrilled, uh, with the very successful results, uh, of the Ignore No More Campaign. This campaign was focused on African American women and sarcoidosis. It was just an incredible reach with over 500,000 media impressions. We were so thrilled to have Gerald Prescott Galen, who's an actress of AMC's Walking, uh, Dead, and Bets All the Queen's Men. She's been living with sarcodosis for many years, but most recently was diagnosed with cardiac sarcodosis. She's been an amazing PSA for us that got over 1000 views in just one month and really helping to amplify our uh, messaging about this really critically important, uh, work. As you know, African American women have the highest prevalence of sarcodosis and by far the worst outcomes. And so it's important that the African American, uh, community understand this and also that clinicians understand this. And so that's what this was really uh, all about. This campaign. We're um, really excited as part two, we've just gotten uh, funding for uh, a part two campaign that's, uh, going to be called Ignore No More Act. Now act stands for Advanced Clinical Trials, Equity in Sarcodosis. And this is really going to be taking a deeper dive into how we um, can support and encourage clinical trial participation, uh, among all African Americans. Um, and our goal is to really learn from the community and to create strategies that can be captured in white paper, uh, and will be helpful tool for, again, both academic as well as, uh, industry sponsored trials. And we're really excited to be, as part of this campaign, hosting a congressional briefing to drive change at the federal level. So I hope listeners stay tuned for this really exciting expansion of this national campaign, and thank you for asking that question. We also have a Chance Zuckerberg initiative going on. I'll turn it over to tricia. She's been working very closely with the Chan Zuckerberg group, uh, on this exciting diversity campaign as, um, well, yeah, so. Tricha Chivas: The Chanceuckaberg Initiative, I think it's really important to say, for the community. So everyone knows this has been not just a grant and then the work that comes, uh, out of that, but this has really afforded FSR a lot of other opportunities for advancing and growing the skill sets of the staff, for reaching out and understanding from others that are in the network, um, best practices that they're using that we can, uh, then bring back to our community. So this has really afforded us a lot of opportunities in order to expand and grow and move things forward for those living with Sarcoidosis, which is our ultimate goal. The actual grant itself will be looking to work with clinics. So, um, members of the alliance, or, um, others that will be working with those clinics and helping to improve the diagnostic, um, and what we'll call the referral pathway. And what I mean by that is the ways that you get from your local doctor, your, um, local pulmonologist, or your local generalist to those more expert, uh, care. And what is that pathway? Um, and how do we really define that so that we can, again, reduce the amount of time for diagnosis and improve the pathway for treatment, especially if someone's living more rurally and they don't have that kind of connection to a more urban center that might be more, um, advanced in this space? John Carlin: I've never heard of that term before, the referral pathway. And you, um, guys are so good at sort of finding terms because you see this stuff all the time. The individual patient that lives in the middle of north or South Dakota or some rural area, in fact, not too far from where I live here in Virginia. That's what they talk about. They say my doctor had never heard of sarcle dosis before. Um, I'm not in a real large urban area, but we do have a large clinic here. People drive 4 hours to get to where I am in Roanoke, Virginia, for care, because we're the big medical center in this part of the world, right, serving the western half of the state of Virginia. But even here, there are very few Sarca doses patients. I might have been one of six for my Rheumatologist doctor, which is not the same as, um, going to Cleveland Clinic, which is what I ultimately decided to do, where I'm dealing with a center where that's all the doctor sees. So that's not so. That term is a referral pathway, and you're trying to sort of take that from being a rural road to an interstate to get you to that doctor quicker. Tricha Chivas: That's all right. I think for us, what we're trying to do is help to identify those areas where patients are being seen and create a kind of a conversation both ways from, um, the major centers to some of those more local level individuals that are, um, supporting individuals living with Sarcodosis, and then, um, also allowing an opportunity for them to have that conversation back. And because a lot of times, even as you're going to Cleveland Clinic, John, you still have the local doctor that you're going to want to talk to, and giving that kind of conversation, allowing them to get the kind of education they need. And then when a case is more complex or they need more support, they can have that support that way. And that's what we're trying to build. John Carlin: Awesome. So, so many exciting things. Mary, what else can listeners look forward to as we move forward over the next few months? Mary McGowan: Well, we have so many exciting things that we've been talking about going on at FSR. Tricia and I are continuing to speak internationally at different conferences. As a matter of fact, in just two weeks, we're headed to Boston. We're both going to be speaking at the World, uh, Orphan Drug Congress, which is really exciting. It's a very large conference, and it's wonderful to have Sarcoidosis being represented, uh, there at that conference. So we're really looking forward to that. Uh, I think also the viewers, if they want to stay in touch with us in terms of the Clinic Alliance and its growth, if, uh, anybody is being treated at the center or alliance that is not on our web page and would like to share contact information, please, uh, let us know, because we want to ensure that we are reaching out, uh, to everybody to offer this opportunity to bring them into this really extraordinary, uh, unique effort. And also, please sign up for our patient conference, um, July 30 and 31st. It's going to be so exciting this year. Last year, we had over 300 attendees from around the world, so we're really looking forward to a really exciting conference this year as well. So those are just a couple of other events. We have some other events on our web page that are coming up. Uh, we have a couple of, uh, painting sessions, so I would encourage anybody who's listening to please join FSR if you have not, all you, uh, simply do is fill out a quick form with your email and that helps you stay up to date on all of our different events and activities. John Carlin: Okay, so I've got a note here to ask you about life, uh, hacks and living with Sarquoidosis. So how will patients be able to take advantage of those or find out what those are? Tricha Chivas: Sure, I'll jump in if that's okay. Mary. Mary McGowan: Great. Tricha Chivas: The life hacks things that we're trying to do here is learn from folks like you, John. Like, what do you do when the fatigue is overwhelming? Or what do you do when you're just having a really painful day? Or what are those things that you're doing? Life hacks are the tips and tricks that people have used in their own daily lives to navigate the disease and learning from individuals that are living with the disease to, um, do that. So this is going to be one of the exciting kinds of sessions that we're having this year are, um, beyond all of our wonderful chat boards and we have a coffee break that's open and chatting. This session is a chance for people to talk back and forth with one another, um, and share how, um, they are managing their day to day. John Carlin: Got it. Life hacks. I love it. And so can people now sign up? Is there not a discount if you sign, uh, up early? How's that work? Early bird? Is that how that works? And how long is that available? Mary McGowan: Early bird registration right through the end of the month. So it's a great opportunity. And there's also, John's, scholarships that are available. So for people who want to attend the conference, uh, there is a registration fee, but we want to make sure that there are no barriers to anybody joining this conference. So if anybody needs financial assistance, there's information there as part of the registration as well. Uh, and so, please, we, uh, want to be able to ensure that everybody has access to attending this really important educational, global event as part of that. But, yes, please pay attention to, uh, the early bird registration, uh, as well. John Carlin: Got you. And if somebody can't afford it, but they want to be there, we'll find a way to make it happen. Mary McGowan: That's absolutely correct. We want to make sure that everybody has access again, uh, to support education, opportunity to ask questions, all the networking that takes place. We understand that this is critically important to bring people together, living with Sarcoid doses to support one another. And that's what this patient conference is all about. John Carlin: Uh, well, guys, look, we've covered a lot in a short amount of time. I'm just thrilled to have had both of you on. But more than that, thrilled to hear about all the momentum, uh, on all the different fronts. So congratulations on just really getting Sarcudos out there and advancing the cause you really deserve. Kudos. Mary McGowan: Well, thank you, John, and thank you for all that you're doing. These podcasts just really help, uh, to, again, amplify the messaging, the incredible interviews that you've done, the highlights of the campaigns that you continue to do. We are so grateful to you for doing this incredibly important work and sharing, uh, this information worldwide. And so you're, uh, part of the great success, uh, that we are all having, as well as all of the patients, the entire Sarcodosis community. It's everybody working, uh, together to spread the word, to spread the awareness, to engage in initiatives. And this is really the result of everybody's success in working together, um, building this momentum. And we're looking forward to the near future to continue to see great successes on the continuation of this momentum building so rapidly now. John Carlin: All right, well, thank you all very much. Tricha Chivas: Thank you so much. Mary McGowan: James on. Tricha Chivas: We appreciate it.    

“High functioning schizophrenia” is not a clinical diagnosis, but it is a term that is heard often when describing how someone is managing life with schizophrenia. So what exactly does that mean? What criteria do you have to meet to be considered “high functioning”? Host Rachel Star Withers, a diagnosed schizophrenic, and co-host Gabe Howard delve into these intense subjects in this episode of Inside Schizophrenia.  Dr. Matthew Smith joins us who is a Professor of Social Work at the University of Michigan and a researcher of high functioning schizophrenia. To learn more, or read the transcript, please visit the show's official episode page. Guest Bio Matthew J. Smith, PhD, MSW, MPE, LCSW, received his PhD from the University of Wisconsin-Madison and completed post-doctoral fellowships in psychiatric epidemiology and biostatistics at Washington University in St. Louis and in translational neuroscience at Northwestern University. Dr. Smith also completed a fellowship on leading randomized controlled trials to evaluate behavioral interventions through the Office of Behavioral and Social Science Research, National Heart, Lung, and Blood Institute. His primary research interests focus on developing and evaluating technology-based interventions that can be delivered in high schools, community mental health agencies and prisons to improve employment and mental health outcomes for transition-age youth with educational disabilities, adults with severe mental illness and/or other disabilities, and returning citizens. Dr. Smith is currently the principal investigator on five projects funded by the National Institute of Mental Health, the National Institute of Justice, the Kessler Foundation and the Michigan Institute for Clinical & Health Research. See research link below for more information on these projects. Dr. Smith's research team includes full-time staff, postdocs and graduate students. Please email smithumlab@umich.edu about opportunities to join the research team. Inside Schizophrenia Podcast Hosts Rachel Star Withers creates videos documenting her schizophrenia, ways to manage and let others like her know they are not alone and can still live an amazing life. She has written Lil Broken Star: Understanding Schizophrenia for Kids and a tool for schizophrenics, To See in the Dark: Hallucination and Delusion Journal. Fun Fact: She has wrestled alligators. To learn more about Rachel, please visit her website, RachelStarLive.com. Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To learn more about Gabe, please visit his website, gabehoward.com.

MARIO SEDLOCK OF ARK BLOOD INSTITUTE ON MORNING MAYHEM 5-25-22

Melissa has another great guest on today's episode of the podcast.  Join her as she talks with Stephanie Davis, Chair of the Capital Region Women in Bio and Small Business Program Coordinator at the National Heart Lung and Blood Institute for NIH.Stephanie and Melissa discuss Women in Bio and how Stephanie's leadership and volunteer efforts have contributed to success in her career.  She is also sharing how you can leverage Women in Bio for your career whether you are entry level or C-Suite.  We are also talking about the unique challenges of women in the workplace and how to overcome them and get to your next level.In this episode learn:Stephanie's career path and philosophy on career developmentHow Women in Bio can help you get to your next level whether you're entry level, an Executive, or anywhere in betweenThe current obstacles facing women who work in the sciences and what both companies and individuals can do to overcome themOne piece of advice Stephanie wished she had earlier in her careerPlease note: Stephanie joins the podcast in her personal capacity and the views expressed on this podcast do not represent the views of the National Institutes of Health or the Department of Health and Human Services.Mentioned in this episode:Learn more about Women in BioConnect with Stephanie on LinkedInSupporting (Postdoctoral) Women in Bio (Stephanie's article)Work with Melissa 1-1 by scheduling a consultation.Connect with MelissaLinkedInInstagram

If you're around the same age as me, mid-50's, then you have/had a mom that hit menopause around 30-40 years ago during which time many women were put on HRT during post-menopause. HRT started in the 60's, but became very popular in the 90's, when the first clinical trials on HRT and post-menopausal women were started (1991), called the Women's Health Initiative (WHI), launched by the National Heart, Lung, and Blood Institute. In 2002, the first results were shared declaring that HRT had more negative than beneficial effects, thus HRT use dropped dramatically in the US (by 46%). Years later, the WHI trial was reanalyzed and showed that HRT use in younger women or started in the onset of post-menopausal women (within 10 years of their last cycle) had multiple beneficial effects including reduced cardiovascular disease and all-cause mortality, meaning HRT protected against all ways of dying. Needless to say, women are still confused and worried about starting HRT, or BHRT, and are struggling through this phase in their lives with symptoms such as weight gain, cognitive decline/ Alzheimer's disease, loss of lean muscle mass, night sweats, loss of sleep, loss of libido, vaginal dryness, osteoporosis, thinning hair and more. By the time a mid-life woman gets to me, she's already tried out several diets, takes a cocktail of anti-depressants, anti-anxiety and sleep pharmaceuticals, has lost her sex drive, gained weight causing her waist circumference to be well over 30”, placing her in the obesity-category, lost her vitality and has low self-esteem. So, just as the kids are leaving the nest for college, mom feels like crap.On today's episode, my guest and I deep dive into women's health, the misconceptions of HRT and BHRT, and how to best prepare yourself with the correct medical data so that you can make an informed decision for yourself. Dr. Wendie Trubow, MD, is a functional medicine gynecologist. She received her M.D. from Tufts University in 2000 and has been practicing functional medicine since 2009. Through her own struggles with mold and metal toxicity, Celiac disease, and a variety of other health issues, Dr. Trubow developed a deep sense of compassion for what her patients are also experiencing. She is passionate about helping women optimize their health and their lives. There are many different challenges a woman faces in her life: work, home, relationships, spirituality, health, and they are all connected. While her credentials allow Dr. Trubow a solid medical foundation to help women achieve vitality, it was her own health journey that has inspired and supported her methods of care. Dr. Trubow and her husband founded the Five Journeys Functional Medicine Clinic outside of Boston and offer services such as IV Therapy, primary care, women's health and functional medicine.You can contact Dr. Wendie Trubow here:website: www.fivejourneys.comFacebook: @fivejourneysIG: @5journeyshealthTwitter: @5journeyshealth

If you're around the same age as me, mid-50's, then you have/had a mom that hit menopause around 30-40 years ago during which time many women were put on HRT during post-menopause. HRT started in the 60's, but became very popular in the 90's, when the first clinical trials on HRT and post-menopausal women were started (1991), called the Women's Health Initiative (WHI), launched by the National Heart, Lung, and Blood Institute. In 2002, the first results were shared declaring that HRT had more negative than beneficial effects, thus HRT use dropped dramatically in the US (by 46%). Years later, the WHI trial was reanalyzed and showed that HRT use in younger women or started in the onset of post-menopausal women (within 10 years of their last cycle) had multiple beneficial effects including reduced cardiovascular disease and all-cause mortality, meaning HRT protected against all ways of dying. Needless to say, women are still confused and worried about starting HRT, or BHRT, and are struggling through this phase in their lives with symptoms such as weight gain, cognitive decline/ Alzheimer's disease, loss of lean muscle mass, night sweats, loss of sleep, loss of libido, vaginal dryness, osteoporosis, thinning hair and more. By the time a mid-life woman gets to me, she's already tried out several diets, takes a cocktail of anti-depressants, anti-anxiety and sleep pharmaceuticals, has lost her sex drive, gained weight causing her waist circumference to be well over 30”, placing her in the obesity-category, lost her vitality and has low self-esteem. So, just as the kids are leaving the nest for college, mom feels like crap.On today's episode, my guest and I deep dive into women's health, the misconceptions of HRT and BHRT, and how to best prepare yourself with the correct medical data so that you can make an informed decision for yourself. Dr. Wendie Trubow, MD, is a functional medicine gynecologist. She received her M.D. from Tufts University in 2000 and has been practicing functional medicine since 2009. Through her own struggles with mold and metal toxicity, Celiac disease, and a variety of other health issues, Dr. Trubow developed a deep sense of compassion for what her patients are also experiencing. She is passionate about helping women optimize their health and their lives. There are many different challenges a woman faces in her life: work, home, relationships, spirituality, health, and they are all connected. While her credentials allow Dr. Trubow a solid medical foundation to help women achieve vitality, it was her own health journey that has inspired and supported her methods of care. Dr. Trubow and her husband founded the Five Journeys Functional Medicine Clinic outside of Boston and offer services such as IV Therapy, primary care, women's health and functional medicine.You can contact Dr. Wendie Trubow here:website: www.fivejourneys.comFacebook: @fivejourneysIG: @5journeyshealthTwitter: @5journeyshealth

Rachele Pojednic, Ph.D., Ed.M is an assistant professor and program director of exercise science in Norwich University's Health and Human Performance Department and a research associate at the Institute of Lifestyle Medicine at Harvard Medical School. Rachele's work examines nutrition and physical activity education for health care and fitness professionals as well as overall diet, supplementation and physical activity interventions on muscle physiology, chronic disease and healthy aging. She received her doctorate from the Tufts University Friedman School of Nutrition Science and Policy in Biochemical and Molecular Nutrition and Exercise Physiology. She also holds a Master of Education in Physical Education from Boston University and a Bachelor of Science in Cardiopulmonary and Exercise Science from Northeastern University. Her research at Tufts was completed in the Nutrition, Exercise Physiology and Sarcopenia laboratory at the U.S. Department of Argiculture Human Nutrition Research Center on Aging, where she received the Ruth L. Kirschstein National Research Service Award from the National Heart, Lung and Blood Institute. In 2022, she received a ($24,939) Vermont Biomedical Research Network Pilot Award for her project “The Perceived Effect versus Biomarkers of Cannabidiol on Muscle Recovery in Active Adult Women.” Rachele has a passion for science communication and has been a consultant and writer for several organizations. Her work has appeared in Time, Popular Science, Self, Shape, Women's Health, Forbes, Runner's World and Boston magazines. You can find her on Instagram at @rachelepojednic and register for her course on nutrition using this link:  https://strong-process.teachable.com/p/nutrition-for-health-coaches-and-fitness-professionals

 Brooke Simonson is a Certified Nutrition Coach & Weight Loss Expert. She'll be sharing with us today how to make small, gradual tweaks to our nutrition, lifestyle, and outlook so we can drop the extra pounds for good without giving up carbs, without the extreme diet strictness, and without compromising our physical and mental health!  TrustforAmerica'shealth.org states…. The U.S. adult obesity rate is at 42.4%. It's the first time the national rate has passed the 40% mark. Since 2008 it has increased by 26%.  And they are calling it an obesity crisis. So this is a health topic to be aware of. Links: Contact Brook Simonson: https://thehealthinvestment.com   Willpower Doesn't Work By Benjamin Hardy: https://www.amazon.com/Willpower-Doesnt-Work-audiobook/dp/B07BH2836Z/ref=sr_1_1?crid=9FUVSKHJPVD8&dchild=1&keywords=willpower+doesnt+work+benjamin+hardy&qid=1633467881&sprefix=willpower+doesnt+%2Caps%2C226&sr=8-1 The 10 Best Ways to Measure Your Body Fat Percentage: https://www.healthline.com/nutrition/ways-to-measure-body-fat   Body Fat Percentage Charts: https://www.medicalnewstoday.com/articles/body-fat-percentage-chart#chart   Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/obesity/diagnosis-treatment/drc-20375749     Trust for America's Health: https://www.tfah.org/report-details/state-of-obesity-2020/   National Heart, Lung, and Blood Institute: https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm   Stay In Touch with Us! Instagram:       @DiscoveringTrueHealth Twitter:            @DTrueHealth  Facebook:       @discoveringtruhealth Rumble:          Discoveringtruehealth YouTube:       youtube.com/channel/UCTzEbcJTQviRusv2dDORRhQ   www.discoveringtruehealth.com  

Roses are red, and love is complicated. What do you think of when you think about love? It's messy, confusing, and often overlooked in how important it is in our walk. If you're not careful, you can end up walking around life with more than a broken heart but a fractured life. Love has got to do with more than just a feeling. A discussion on how everything we do in life is related to how we love God, His people, and ourselves. Tune in for our episode today as I share what's missing your love life for 2022. Seeds from Today's EpisodeIf you're interested in learning more about ways to support your heart and your health check out the National Heart, Lung and Blood Institute.Scriptures from the episode1 Corinthians 13:1-8Jeremiah  29:11-13Join us for a new episode bi-weekly on Wednesdays!If you need prayer, email info@bigboldfaith.comWant to support the podcast financially, learn more about our mission and see how we live Ordinarily Bold daily? Follow us or visit us at the below links:Website: www.bigboldfaith.comPartner with Us: https://www.bigboldfaith.com/supportFind Us: @bigboldfaithSupport the show

LISTEN to my March 31st, 2021 WIOX show with my guest co-host, the erudite poet and novelist, Lee Slonimsky.  Lee invited poet and eminent physician Robert Charles Basner to read and discuss his evocative and original poetry.  Robert Charles Basner, holds the titles of Professor Emeritus of Medicine, Columbia University, and Special Lecturer in Medicine, Columbia University Irving Medical Center. He is an internationally recognized physician and biomedical researcher, author, editor, editorialist, and educator. A former faculty member of the Harvard Medical School and current faculty member of his alma mater, the Columbia University College of Physicians and Surgeons, he is a laureate of an NIH Academic Career Award of the National Heart, Lung, and Blood Institute, and of the Sidney Zolot Music Award of the City College of New York. He has published poetry in numerous journals including the Columbia Review, Promethean, and Chronogram and is working on a first collection of verse, “Ancient, Autumnal” as well as a sequence of musical settings for voice and viola.  Lee Slonimsky has published nine full-length volumes of poetry.  His third book, Pythagoras in Love, has been translated into French by Elizabeth J. Coleman, Greek by Stamatis Polenakis, and most recently into Polish by Henryk Cierniak.  With his wife, Hammett and Mary Higgins Clark award winning mystery writer Carol Goodman, under the pen name Lee Carroll, Lee has co-written the Black Swan Rising trilogy featuring vampire hedge fund manager and poet Will Hughes.

In This episode, Dr. Gary Sherman welcomes Dr. Anu Lala to our conversation. Dr. Lala's clinical interests encompass all aspects of management of heart failure, including the selection and care of patients with mechanical circulatory support devices and heart transplantation as well as genetic cardiomyopathies -and- perioperative management of high-risk cardiac surgical cases. She believes in a patient-centered approach, where each individual's unique needs and preferences are essential components of developing a personalized treatment plan. Dr. Lala seeks to implement -guideline-directed -medical and device-based therapies while integrating emotional and spiritual aspects of care. (This is right up my alley) In addition to caring for patients, she serves as the Director of Heart Failure Research and as Data Coordinating Center Leader for the National Heart Lung and Blood Institute's (NHLBI) Cardiothoracic Surgery Network. Dr. Lala also leads the fellowship program in Advanced Heart Failure and Transplant. She has authored over 75 peer-reviewed scientific publications and is the principal investigator for a number of clinical trials in heart failure. Dr. Lala serves on local and national committees in the American Heart Association, American College of Cardiology, Heart Failure Society of America among others, devoted to advanced heart disease. In 2016, Dr Lala was named the American Heart Association Young Professionals Society Honoree for her service and commitment to education - and promoting cardiovascular health awareness. In 2020, she was recognized with the Proctor H. Harvey Teaching Award by the American College of Cardiology which honors a promising young member of the College who has distinguished herself by dedication and skill in teaching, and to stimulate continued careers in education.References:Dr. Anuradha Lala Tridade:  : https://www.mountsinai.org/profiles/anuradha-lala-trindadeThere's more to life than being happy | Emily Esfahani Smith:  https://youtu.be/y9Trdafp83UStrategic Empathy approaches: Never Split the Difference: Negotiating As If Your Life Depended On It , Chris Voss, Tahl Raz

This week on The Rose Woman Pod, Neuropsychiatrist Louann Brizendine discusses the latest science on the Female Brain. The stages of a woman's life, from birth to menopause and how hormones trigger feelings, behaviors and skills.Louann Brizendine, M.D. completed her degree in Neurobiology at UC Berkeley, graduated from Yale School of Medicine and did her internship and residency at Harvard Medical School. She has also served on both the faculties of Harvard University and University of California at San Francisco. She founded the Women's Mood and Hormone Clinic at UCSF. Her NY Times bestseller: “The Female Brain” and its follow-up, “The Male Brain continue to be read around the world. Now as the Benioff endowed professor of clinical psychiatry at UCSF, Dr. Brizendine, continues to mentor, speak, write, consult with start-up companies and see patients.Her upcoming book The Upgrade: How the Female Brain Remakes Itself for the Better in the Second Half of Life” will be published in April 2022.In this episode, we cover:Louann's upcoming new book “The Upgrade: How the Female Brain Remakes Itself for the Better in the Second Half of Life” Infantile Puberty Learn about the functions of hormones like Ghrelin, Leptin, Estrogen, Oxytocin (and many more) and what it does on female and male behaviorBioidentical hormones Is there a way to track hormones?The transition to menopauseExperiences of both women and men in hormonal change in different stages Helpful Links:Dr Louann Brizendine - Author of NY Times Best Seller: The Female Brain and the The Male Brain. Check out her Facebook and TwitterThe Female Brain Movie (2017) - Romantic-comedy film based on The Female Brain book by Dr. Louann BrizendineThe Women's Health Initiative - (WHI) is a long-term national health study funded by the National Heart, Lung, and Blood Institute, or NHLBIFind Rosebud Woman on Instagram as @rosebudwoman and Christine on Instagram as @the.rose.woman See acast.com/privacy for privacy and opt-out information.

The Floridaville Get to Know the People Behind the Florida Names You Know Zachariah P. Zachariah MD is the current Chair of the Florida Board of Medicine.  He is a cardiologist who has spent his life serving his community.  He serves as a member of the National Heart, Lung and Blood Institute of the National Institute of Health. He also serves as a member of the Board of Trustees of Nova Southeastern University, a member of the Council of 100, and numerous government and private sector boards.  

In December 2020, the National Heart, Lung and Blood Institute released an update on its asthma guidelines - the first update since the original guidelines came out in 2007. Join Dr. Sufcak and Dr. Miller as we discuss how these guidelines impact our management of asthma as general practitioners. More information can be found on mdnotified.com.

For this episode, we will be reviewing three articles about asthma from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch We're pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk Article Links: Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.  Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.